mitomycin has been researched along with Breast Cancer in 398 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the management of doxorubicin (ADR)-refractory advanced breast cancer, combination chemotherapies including mitomycin C (MMC) have been widely acknowledged to have definitive therapeutic effects." | 10.18 | [Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer]. ( Nomura, Y; Shirouzu, M; Takayama, T; Tashiro, H, 1996) |
| "Investigators have compiled extensive experience with mitomycin in the treatment of patients with breast cancer." | 10.17 | Mitomycin: its evolving role in the treatment of breast cancer. ( Hortobagyi, GN, 1993) |
| "Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine." | 10.16 | Mitomycin-C and vinblastine in advanced breast cancer. ( Balañá, C; Bellmunt, J; Colomer, R; del Campo, JM; Jolis, L; Navarro, M, 1989) |
| "We sequenced ATM and assessed gene expression levels in pre-treatment biopsies from 71 locally advanced breast cancers treated in the neoadjuvant setting with doxorubicin monotherapy or mitomycin combined with 5-fluorouracil." | 9.16 | Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. ( Anker, G; Chrisanthar, R; Knappskog, S; Leirvaag, B; Lundgren, S; Løkkevik, E; Lønning, PE; Miletic, H; Mjaaland, I; Risberg, T; Østenstad, B, 2012) |
| "Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity." | 9.16 | Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer. ( Blohmer, JU; du Bois, A; Lück, HJ; Schippert, C; Warm, M, 2012) |
| "A randomized phase II study using mitomycin (MMC)/cisplatin (DDP) regimen with or without Kanglaite (KLT, a traditional Chinese medicine) as salvage treatment was conducted to exploit KLT's potential effects on patients with advanced breast cancer (ABC)." | 9.13 | Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer. ( Cai, Y; Guo, HY; Hu, XC; Li, J; Wang, JL; Wang, ZH; Yang, XM; Zhao, XM, 2008) |
| "To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer." | 9.11 | Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. ( Alland, L; Erazo, A; Georgoulias, VA; Henderson, IC; Kaufmann, M; Keller, AM; Lluch, A; Mellars, L; Mennel, RG; Nabholtz, JM; Tendler, C; Vogel, CL; von Minckwitz, G, 2004) |
| "This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy." | 9.11 | Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. ( Archer, CD; Assersohn, LA; Gregory, RK; Johnston, SR; Mendes, R; Smith, IE; Urruticoechea, A; Verrill, M; Walsh, G, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | 9.08 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "A phase II trial was performed to evaluate the efficacy and tolerance of vinorelbine (VNB), mitomycin C (MMC), and recombinant human granulocyte colony-stimulating factor (G-CSF) in advanced breast cancer." | 9.08 | Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. ( Burger, D; Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Meghdadi, S; Raderer, M; Scheithauer, W; Schneeweiss, B, 1996) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 9.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 9.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i." | 9.07 | Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. ( Agostara, B; Callari, AM; Cusimano, MP; Gebbia, N; Gebbia, V; Testa, A, 1994) |
| "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle." | 9.07 | Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994) |
| "In February 1986 we began a study to test the activity of mitomycin C (12 mg/m2) plus vinblastine (6 mg/m2) on day 1 of a 28-day cycle (MV) as second or third-line chemotherapy for metastatic breast cancer patients." | 9.07 | Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gridelli, C; Nuzzo, F; Pagliarulo, C; Perrone, F; Ruggiero, A, 1993) |
| "A randomized study assessing the efficacy of three treatment of ftorafur (FT), ftorafur plus Tamoxifen (TAM), and Tamoxifen in patients diagnosed as having stage II (N1b) or stage III breast cancer was carried out at 90 institutions in the Chubu district of Japan." | 9.07 | [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan]. ( Kobayashi, S; Miyazaki, I; Mizumoto, R; Nimura, Y; Noguchi, M; Saji, S; Takagi, H; Takeuchi, S; Tsuda, H; Yoshida, M, 1993) |
| "The efficacy and toxicity of navelbine 30 mg/m2 administered intravenously (IV) over 30 minutes every 3 weeks, and mitomycin C 15 mg/m2 administered IV every 6 weeks was assessed in 34 patients with metastatic breast cancer refractory to first-line chemotherapy." | 9.07 | Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. ( Depisch, D; Haider, K; Kornek, G; Kwasny, W; Pirker, R; Scheithauer, W; Schenk, T, 1993) |
| "Seventy-six women with previously treated breast cancer were randomized to receive mitomycin (M) or M plus high-dose oral medroxyprogesterone acetate (MMPA)." | 9.07 | A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. ( Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC, 1993) |
| "Thirty-three patients with advanced and refractory breast cancer were treated with two mitoxantrone-containing regimens (mitoxantrone plus mitomycin and mitoxantrone plus mitomycin plus methotrexate)." | 9.07 | Salvage chemotherapy with mitoxantrone and mitomycin with or without methotrexate in advanced breast cancer. ( Astone, A; Barone, C; Cassano, A; Fontana, T; Noviello, MR; Pozzo, C, 1992) |
| "This paper describes a randomised clinical trial in patients with advanced breast cancer, comparing the regimen 3M, mitomycin C 7-8 mg m-2 (day 1), mitozantrone 7-8 mg m-2 (day 1 and 21), methotrexate 35 mg m-2 (day 1 and 21) given on a 42 day cycle with a standard anthracycline containing regimen, VAC, vincristine 1." | 9.07 | A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. ( Ashley, SE; Hardy, JR; Jones, AL; Judson, IR; Powles, TJ, 1991) |
| "Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer." | 9.07 | A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. ( Ashley, S; Jodrell, DI; Mansi, JL; McKinna, JA; Pearson, MC; Sinnett, HD; Smith, IE; Walsh, G, 1991) |
| "In an attempt to examine the possibility of decreased toxicity in patients with advanced breast cancer who had not previously received chemotherapy, 33 women were given combination chemotherapy consisting of mitomycin C (10 mg/m2) every 6 weeks and mitoxantrone (6 mg/m2) every 3 weeks." | 9.06 | Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. ( Begin, L; Margolese, R; Panasci, L; Pollak, M; Reinke, A; Shenouda, G, 1990) |
| "Thirty-two patients with advanced breast cancer were treated with mitomycin-C 10 mg/m2 IV and vinblastine 6 mg/m2 IV every 21 days in combination with lonidamine 450 mg/day P." | 9.06 | Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study. ( Arcangeli, G; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Simoncini, E; Zaniboni, A, 1990) |
| "Of 47 consecutive patients with advanced breast cancer, we randomly assigned 24 to receive Arm A; ACF alone (Adriamycin, Cyclophosphamide, Ftorafur) and 23 to receive Arm B; 2 cycles of ACF alternating one cycle of MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur--a combination of drugs not cross-resistant with ACF)." | 9.06 | [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Tada, A; Ueno, K; Yamazaki, H, 1989) |
| "64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy." | 9.06 | Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. ( Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989) |
| "A randomized clinical trial was performed to determine if combination therapy with doxorubicin, vincristine, and mitomycin C (DVM) was superior to doxorubicin alone in women with metastatic breast cancer for whom prior chemotherapy had failed." | 9.06 | Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. ( Foley, JF; Gerstner, JB; Ingle, JN; Krook, JE; Long, HJ; Mailliard, JA; Marschke, RF; McCormack, GW; Pfeifle, DM; Schaid, DJ, 1989) |
| "Forty women with metastatic breast cancer were randomized to receive either mitomycin-C (MMC) (21 patients) or vindesine (19 patients) with high dose medroxyprogesterone acetate (MPA)." | 9.06 | High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer. ( Falkson, CI; Falkson, G; Falkson, HC, 1988) |
| "One hundred and thirty-one patients (118 evaluable) with disseminated breast cancer were treated with a combination of 5-fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM)." | 9.05 | 5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): an effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study. ( Cassidy, MJ; Cruicitt, M; Friedman, MA; Hendrickson, CG; Johnson, D; Kilbridge, T; Kohler, M; Marcus, FS; Resser, KJ; Reynolds, R; Yu, K, 1983) |
| "We report a case of acute fatal respiratory failure following mitomycin and vinblastine administration in a patient with metastatic breast cancer." | 8.77 | Fatal acute respiratory failure following vinblastine and mitomycin administration for breast cancer. ( Ballen, KK; Weiss, ST, 1988) |
| "Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer." | 8.77 | Mitomycin C in advanced breast cancer: an update. ( Godfrey, TE, 1988) |
| "Mitomycin C is a chemotherapeutic agent active against breast cancer." | 8.77 | Mitomycin C in the chemotherapy of advanced breast cancer. ( Garewal, HS, 1988) |
| "Background The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (90Y) resin microspheres in liver metastatic breast cancer (LMBC) patients." | 7.96 | Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. ( Aarts, BM; Beets-Tan, RGH; Deroose, CMALO; Dresen, RC; Klompenhouwer, EG; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2020) |
| "Mitomycin C (MMC) is an anti-cancer drug used for the treatment of breast cancer with limited therapeutic index, extreme gastric adverse effects and bone marrow suppression." | 7.91 | LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An ( Aghaei, M; Aliomrani, M; Azizi, R; Sarrami, N; Varshosaz, J, 2019) |
| "The aim of this study was to determine the safety and efficacy of Mitomycin C (MMC) infusion in a large cohort of advanced liver metastatic breast cancer patients (LMBC) and to determine factors influencing overall survival (OS)." | 7.91 | Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. ( Aarts, BM; Beets-Tan, RGH; Dresen, RC; Klompenhouwer, EG; Laenen, A; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2019) |
| "The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine." | 7.83 | Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. ( Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG, 2016) |
| " The current study investigated the potential of curcumin to reduce breast cancer stem cell (BCSC) population for sensitizing breast cancer cells to mitomycin C (MMC) both in vitro and in vivo." | 7.81 | Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells. ( Chen, Q; Huang, S; Lu, Y; Su, S; Ye, M; Zhang, H; Zhou, Q, 2015) |
| "In order to explore the synergistic mechanisms of combinatorial treatment using curcumin and mitomycin C (MMC) for breast cancer, MCF-7 breast cancer xenografts were conducted to observe the synergistic effect of combinatorial treatment using curcumin and MMC at various dosages." | 7.80 | Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. ( Chen, QL; Du, J; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhou, QM, 2014) |
| " TP53 mutations, in particular those affecting the L2/L3 domains, are associated with resistance to anthracycline or mitomycin treatment in breast cancer patients." | 7.79 | Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. ( Berge, EO; Huun, J; Knappskog, S; Lillehaug, JR; Lønning, PE, 2013) |
| "Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM)." | 7.78 | Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study. ( Aldabbagh, K; Fabbro, M; Jacot, W; Pouderoux, S; Poujol, S; Roca, L; Romieu, G, 2012) |
| "To investigate the efficacy of mitomycin C (MMC) in combination with curcumin in suppressing human breast cancer in vitro and in vivo." | 7.77 | Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. ( Liu, XJ; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhou, QM, 2011) |
| "The aim of this retrospective study was to evaluate the activity and toxicity of a combined chemotherapy containing mitomycin, folinate, and 5-fluorouracil (MiFoFU) in patients with advanced metastatic breast cancer and reduced performance status, ie, elderly patients or heavily pretreated patients." | 7.74 | Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis. ( Bruckner, T; Eichbaum, MH; Gast, AS; Schneeweiss, A; Sohn, C, 2007) |
| "In the treatment of extensive liver metastasis of breast cancer (LMBC), locally administered Mitomycin C (MMC) to the liver might be an effective approach with limited toxicity." | 7.74 | Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer. ( Demey, W; Heye, S; Maes, T; Maleux, G; Neven, P; Paridaens, R; Van Oosterom, AT; Wildiers, H, 2008) |
| "The combination of doxorubicin and mitomycin C has been shown previously to result in supra-additive tumor cell killing in vitro in both murine and human breast cancer cells and in vivo against murine breast cancer cells." | 7.74 | On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. ( O'Brien, PJ; Rauth, AM; Shuhendler, AJ; Wu, XY, 2007) |
| "Thirty-five patients with locally advanced breast cancer were investigated for TP53 mutations before receiving combination chemotherapy with 5-fluorouracil (1000 mg/m(2) on days 1 and 2) and mitomycin (6 mg/m(2) on day 2), administered every 3 weeks for 2-10 cycles in the neoadjuvant setting." | 7.72 | TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. ( Aas, T; Akslen, LA; Anker, G; Børresen-Dale, AL; Geisler, J; Geisler, S; Johnsen, H; Lønning, PE, 2003) |
| " We investigated p21 and p21B for mutations and epigenetic silencing in locally advanced breast cancers treated with doxorubicin or 5-fluorouracil/mitomycin and correlated our findings with treatment response and TP53 status." | 7.72 | Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. ( Leirvaag, B; Lillehaug, JR; Lønning, PE; Staalesen, V, 2004) |
| "Centchroman (CC), a non-steroidal oral contraceptive and a candidate drug for breast cancer, has been reported to exhibit partial to complete remission of lesions in 40." | 7.70 | Antimutagenic effects of centchroman--a contraceptive and a candidate drug for breast cancer in multiple mutational assays. ( Giri, AK; Hsie, AW; Mukhopadhyay, A; Ray, S; Sun, J, 1999) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 7.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks." | 7.68 | Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. ( Campora, E; Gardin, G; Giudici, S; Merlini, L; Miglietta, L; Naso, C; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1992) |
| "A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer." | 7.68 | Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. ( D'Alessandro, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A, 1991) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | 7.68 | [5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "Adriamycin and mitomycin C in combination have been tested in the treatment of advanced breast cancer." | 7.67 | Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer. ( Amiel, SA; Earl, HM; Knight, RK; Rubens, RD; Stewart, JF, 1984) |
| "The influence of family history, irradiation and anti-cancer drug (Mitomycin C) on the occurrence of multiple primary neoplasms was analysed using the person-year method in 1359 Japanese breast carcinoma patients." | 7.67 | [Influence of family history, irradiation and anti-cancer drug (mitomycin C) on the occurrence of multiple primary neoplasms in breast carcinoma patients]. ( Fukami, A; Kasumi, F; Kuno, K; Sakamoto, G; Sugano, H; Yoshimoto, M, 1984) |
| "Twenty-six patients with advanced breast cancer, (12 previously treated with adriamycin-containing regimens, 14 not exposed to adriamycin because of poor cardiac performance), were treated with combination chemotherapy including mitomycin C plus 5-fluorouracil." | 7.67 | Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients. ( Ardizzoni, A; Conte, PF; Pronzato, P; Rosso, R, 1984) |
| "A 49 year old woman treated for metastatic adenocarcinoma of the breast suddenly developed the symptoms of acute pulmonary edema 90 minutes after infusion of mitomycin C/vinblastine." | 7.67 | [Acute dyspnea following intravenous administration of vinblastine/mitomycin C]. ( Gattiker, HH; Lagler, U, 1989) |
| "A combination of mitomycin C and vinblastine was administered as salvage treatment in 44 patients with heavily pretreated refractory breast cancer." | 7.67 | Mitomycin C and vinblastine in advanced refractory breast cancer. ( Bonadonna, G; Brambilla, C; Ferrari, L; Zambetti, M, 1989) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 7.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i." | 7.67 | Etoposide and mitomycin-C in pretreated metastatic breast cancer. ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989) |
| "In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied." | 7.67 | [Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985) |
| "Forty-nine patients with liver metastases of breast cancer were treated with arterial infusion involving simultaneous use of adriamycin: 30-50 mg and mitomycin C: 10-20 mg through the hepatic artery by Seldinger catheter." | 7.67 | [Arterial infusion of combination chemotherapy consisting of adriamycin and mitomycin C for liver metastases of breast cancer]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Tada, A; Ueno, K; Yamazaki, H, 1986) |
| "Fifty-seven patients with advanced breast cancer were treated with a combination of 5-fluorouracil and mitomycin C (FuMi)." | 7.67 | 5-Fluorouracil and mitomycin C in advanced breast cancer. ( Aspegren, K; Landberg, T, 1986) |
| "Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active." | 7.67 | Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. ( Dees, A; Stoter, G; van Putten, WL; Verweij, J, 1987) |
| "The effect of preoperative intra-arterial infusion of mitomycin C, 5-fluorouracil (5-FU) and adriamycin (ADM) were studied in seven patients with locally advanced breast cancer, including five inflammatory carcinomas, and a patient with stromal sarcoma of the breast." | 7.67 | [Preoperative intra-arterial infusion chemotherapy in locally advanced primary breast cancer-tissue concentrations of 5-fluorouracil and adriamycin, and the histological evaluation]. ( Ikoma, M; Ishikawa, H; Kasahara, M; Murayama, N; Shimada, A; Takenaka, Y; Watanabe, M; Yoshida, H, 1988) |
| "The influence of family history of cancer, radiation therapy and anticancer drug therapy (mitomycin C) on the occurrence of multiple primary neoplasms, following treatment of a first primary cancer of the breast, was analyzed by the person-year method in 1,359 patients, in Japan." | 7.67 | The influence of family history of cancer, irradiation and anticancer medication (mitomycin C), on the occurrence of multiple primary neoplasms with breast cancer--statistical analysis by the person-year method. ( Fukami, A; Kajitani, T; Kasumi, F; Nishi, M; Sakamoto, G; Yoshimoto, M, 1985) |
| "Eight previously irradiated breast cancer patients with local recurrences were treated with intra-arterial infusions of 8 mg/m2 mitomycin C given at 3-week intervals." | 7.67 | Intra-arterial infusion of mitomycin C in treatment of breast cancer: occurrence of skin necrosis in irradiated patients. ( Fodstad, O; Gundersen, S; Hager, B; Kvalheim, G, 1985) |
| "Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks." | 7.67 | Mitomycin C and vinblastine in the treatment of advanced breast cancer. ( Knight, RK; Radford, JA; Rubens, RD, 1985) |
| "43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i." | 7.66 | Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | 7.66 | [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "Mitomycin C together with either vindesine or vinblastine was given to 48 patients with previously treated advanced breast cancer." | 7.66 | Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. ( Brooks, RJ; Garewal, HS; Jones, SE; Miller, TP, 1983) |
| "In a Phase II study, 50 patients with advanced breast cancer were treated with a combination of 5-fluorouracil (1000 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen)." | 7.66 | A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. ( Bjelkengren, G; Hallsten, L; Mattsson, W; von Eyben, F, 1982) |
| "One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks." | 7.66 | [Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]. ( Brunet, R; Bui, BN; Chauvergne, J; Durand, M; Hoerni, B; Mauriac, L, 1981) |
| "Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin." | 7.66 | Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report. ( Oster, MW; Park, Y, 1983) |
| "Treatment with mitomycin-C only showed median and mean survival times of 13." | 6.75 | Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. ( Eichler, K; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S, 2010) |
| "Overall, 77." | 6.72 | Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | 6.70 | Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| "Patients with advanced breast cancer were randomised to 3M (mitozantrone 6." | 6.67 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. ( Barton, C; Bliss, JM; Bower, M; Coombes, RC; Ford, HT; Gazet, JC; Law, M; Stein, RC, 1992) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 6.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "In five heavily pretreated women with breast cancer, one patient had a complete response, one patient had a partial response, and one patient had stable disease." | 6.42 | Rationale for mitomycin and irinotecan use in advanced breast cancer. ( Shapiro, CL; Xu, Y, 2003) |
| "Mitomycin-C is an effective antitumor agent in breast cancer and should be carefully incorporated in the therapeutic strategy of this disease." | 6.37 | Mitomycin-C in breast cancer. ( Hortobagyi, GN, 1985) |
| "In the management of doxorubicin (ADR)-refractory advanced breast cancer, combination chemotherapies including mitomycin C (MMC) have been widely acknowledged to have definitive therapeutic effects." | 6.18 | [Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer]. ( Nomura, Y; Shirouzu, M; Takayama, T; Tashiro, H, 1996) |
| "Investigators have compiled extensive experience with mitomycin in the treatment of patients with breast cancer." | 6.17 | Mitomycin: its evolving role in the treatment of breast cancer. ( Hortobagyi, GN, 1993) |
| "Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine." | 6.16 | Mitomycin-C and vinblastine in advanced breast cancer. ( Balañá, C; Bellmunt, J; Colomer, R; del Campo, JM; Jolis, L; Navarro, M, 1989) |
| " Under the diagnosis of cardiac tamponade, we treated her with pericardial drainage and systemic chemotherapy (intravenous dosage of trastuzumab and vinorelbine: VNR), and then pericardial effusion disappeared." | 5.36 | [A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillations of OK-432 and mitomycin C]. ( Fujita, M; Matsuura, O; Morohashi, H; Morohashi, S; Nishimura, A; Yakoshi, Y; Yamada, K; Yonaiyama, S, 2010) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 5.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| "Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)." | 5.35 | Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009) |
| "Mitomycin C (MMC) is a DNA cross-linking agent that has been used in cancer chemotherapy for >20 years." | 5.31 | Detection of mitomycin C-DNA adducts in human breast cancer cells grown in culture, as xenografted tumors in nude mice, and in biopsies of human breast cancer patient tumors as determined by (32)P-postlabeling. ( Hamilton, JW; Mustra, DJ; Warren, AJ, 2001) |
| "For these studies, MKN-74 gastric cancer cells and MDA-MB-468 breast cancer cells were exposed to either no drug, 1 microgram/ml MMC alone, 300 nM flavopiridol alone, or a combination of chemotherapy with flavopiridol for 24 h." | 5.30 | Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. ( Farsi, K; Kelsen, DP; Maslak, P; Schwartz, GK; Spriggs, D, 1997) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | 5.28 | [Clinical efficacy of ifosfamide for liver metastasis of breast cancer]. ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | 5.27 | Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| "We sequenced ATM and assessed gene expression levels in pre-treatment biopsies from 71 locally advanced breast cancers treated in the neoadjuvant setting with doxorubicin monotherapy or mitomycin combined with 5-fluorouracil." | 5.16 | Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. ( Anker, G; Chrisanthar, R; Knappskog, S; Leirvaag, B; Lundgren, S; Løkkevik, E; Lønning, PE; Miletic, H; Mjaaland, I; Risberg, T; Østenstad, B, 2012) |
| "Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity." | 5.16 | Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer. ( Blohmer, JU; du Bois, A; Lück, HJ; Schippert, C; Warm, M, 2012) |
| "A randomized phase II study using mitomycin (MMC)/cisplatin (DDP) regimen with or without Kanglaite (KLT, a traditional Chinese medicine) as salvage treatment was conducted to exploit KLT's potential effects on patients with advanced breast cancer (ABC)." | 5.13 | Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer. ( Cai, Y; Guo, HY; Hu, XC; Li, J; Wang, JL; Wang, ZH; Yang, XM; Zhao, XM, 2008) |
| "Of our study was to assess and compare the outcome of patients undergoing anthracycline based neoadjuvant chemotherapy in locally advanced primary breast cancers with patients receiving mitoxantrone, methotrexate and mitomycin (MMM) as neoadjuvant agents." | 5.12 | Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience. ( Agrawal, A; Asgeirsson, KS; Chan, SY; Cheung, KL; Ellis, IO; Mathew, J; Mukherjee, A; Robertson, JF, 2007) |
| "To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer." | 5.11 | Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. ( Alland, L; Erazo, A; Georgoulias, VA; Henderson, IC; Kaufmann, M; Keller, AM; Lluch, A; Mellars, L; Mennel, RG; Nabholtz, JM; Tendler, C; Vogel, CL; von Minckwitz, G, 2004) |
| "This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy." | 5.11 | Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. ( Archer, CD; Assersohn, LA; Gregory, RK; Johnston, SR; Mendes, R; Smith, IE; Urruticoechea, A; Verrill, M; Walsh, G, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "According to estrogen receptor (ER) and menopausal status, operable breast cancer patients were randomized for adjuvant endocrine therapy with tamoxifen (TAM) in premenopausal patients, after oophorectomy (OVEX), chemotherapy, CHEM (mitomycin C+ oral cyclophosphamide), or chemo-endocrine therapy (TAM + CHEM)." | 5.09 | [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status]. ( Murakami, S; Nomura, Y; Takenaka, Y; Tsutsui, S, 1999) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | 5.08 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "Between 1985 and 1988, the effect of using ftorafur (FT) or PSK (an immunotherapy agent) in combination with the conventional postoperative adjuvant therapy using mitomycin (MMC) plus tamoxifen (TAM) was assessed in stage II, oestrogen receptor-positive (ER+) breast cancer patients." | 5.08 | Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can ( Dohi, K; Monden, Y; Morimoto, T; Nomura, Y; Ogawa, M; Ogawa, N; Orita, K; Sugimachi, K; Toge, T, 1996) |
| "A phase II trial was performed to evaluate the efficacy and tolerance of vinorelbine (VNB), mitomycin C (MMC), and recombinant human granulocyte colony-stimulating factor (G-CSF) in advanced breast cancer." | 5.08 | Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. ( Burger, D; Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Meghdadi, S; Raderer, M; Scheithauer, W; Schneeweiss, B, 1996) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 5.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 5.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i." | 5.07 | Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. ( Agostara, B; Callari, AM; Cusimano, MP; Gebbia, N; Gebbia, V; Testa, A, 1994) |
| "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle." | 5.07 | Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994) |
| "In February 1986 we began a study to test the activity of mitomycin C (12 mg/m2) plus vinblastine (6 mg/m2) on day 1 of a 28-day cycle (MV) as second or third-line chemotherapy for metastatic breast cancer patients." | 5.07 | Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gridelli, C; Nuzzo, F; Pagliarulo, C; Perrone, F; Ruggiero, A, 1993) |
| "A randomized study assessing the efficacy of three treatment of ftorafur (FT), ftorafur plus Tamoxifen (TAM), and Tamoxifen in patients diagnosed as having stage II (N1b) or stage III breast cancer was carried out at 90 institutions in the Chubu district of Japan." | 5.07 | [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan]. ( Kobayashi, S; Miyazaki, I; Mizumoto, R; Nimura, Y; Noguchi, M; Saji, S; Takagi, H; Takeuchi, S; Tsuda, H; Yoshida, M, 1993) |
| "A comparison of patients receiving combination chemotherapy with mitomycin C, mitozantrone and methotrexate (3M) with and without tamoxifen for treatment of primary breast cancer indicates an increased risk of anaemia (P < 0." | 5.07 | A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. ( Ashley, SE; Luckit, J; Montes, A; O'Brien, ME; Powles, TJ; Treleaven, J, 1993) |
| "The efficacy and toxicity of navelbine 30 mg/m2 administered intravenously (IV) over 30 minutes every 3 weeks, and mitomycin C 15 mg/m2 administered IV every 6 weeks was assessed in 34 patients with metastatic breast cancer refractory to first-line chemotherapy." | 5.07 | Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. ( Depisch, D; Haider, K; Kornek, G; Kwasny, W; Pirker, R; Scheithauer, W; Schenk, T, 1993) |
| "Seventy-six women with previously treated breast cancer were randomized to receive mitomycin (M) or M plus high-dose oral medroxyprogesterone acetate (MMPA)." | 5.07 | A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. ( Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC, 1993) |
| "Thirty-three patients with advanced and refractory breast cancer were treated with two mitoxantrone-containing regimens (mitoxantrone plus mitomycin and mitoxantrone plus mitomycin plus methotrexate)." | 5.07 | Salvage chemotherapy with mitoxantrone and mitomycin with or without methotrexate in advanced breast cancer. ( Astone, A; Barone, C; Cassano, A; Fontana, T; Noviello, MR; Pozzo, C, 1992) |
| "This paper describes a randomised clinical trial in patients with advanced breast cancer, comparing the regimen 3M, mitomycin C 7-8 mg m-2 (day 1), mitozantrone 7-8 mg m-2 (day 1 and 21), methotrexate 35 mg m-2 (day 1 and 21) given on a 42 day cycle with a standard anthracycline containing regimen, VAC, vincristine 1." | 5.07 | A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. ( Ashley, SE; Hardy, JR; Jones, AL; Judson, IR; Powles, TJ, 1991) |
| "Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer." | 5.07 | A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. ( Ashley, S; Jodrell, DI; Mansi, JL; McKinna, JA; Pearson, MC; Sinnett, HD; Smith, IE; Walsh, G, 1991) |
| "In an attempt to examine the possibility of decreased toxicity in patients with advanced breast cancer who had not previously received chemotherapy, 33 women were given combination chemotherapy consisting of mitomycin C (10 mg/m2) every 6 weeks and mitoxantrone (6 mg/m2) every 3 weeks." | 5.06 | Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. ( Begin, L; Margolese, R; Panasci, L; Pollak, M; Reinke, A; Shenouda, G, 1990) |
| "Thirty-two patients with advanced breast cancer were treated with mitomycin-C 10 mg/m2 IV and vinblastine 6 mg/m2 IV every 21 days in combination with lonidamine 450 mg/day P." | 5.06 | Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study. ( Arcangeli, G; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Simoncini, E; Zaniboni, A, 1990) |
| "Of 47 consecutive patients with advanced breast cancer, we randomly assigned 24 to receive Arm A; ACF alone (Adriamycin, Cyclophosphamide, Ftorafur) and 23 to receive Arm B; 2 cycles of ACF alternating one cycle of MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur--a combination of drugs not cross-resistant with ACF)." | 5.06 | [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Tada, A; Ueno, K; Yamazaki, H, 1989) |
| "64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy." | 5.06 | Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. ( Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989) |
| "A randomized clinical trial was performed to determine if combination therapy with doxorubicin, vincristine, and mitomycin C (DVM) was superior to doxorubicin alone in women with metastatic breast cancer for whom prior chemotherapy had failed." | 5.06 | Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. ( Foley, JF; Gerstner, JB; Ingle, JN; Krook, JE; Long, HJ; Mailliard, JA; Marschke, RF; McCormack, GW; Pfeifle, DM; Schaid, DJ, 1989) |
| "Forty women with metastatic breast cancer were randomized to receive either mitomycin-C (MMC) (21 patients) or vindesine (19 patients) with high dose medroxyprogesterone acetate (MPA)." | 5.06 | High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer. ( Falkson, CI; Falkson, G; Falkson, HC, 1988) |
| "One hundred and thirty-one patients (118 evaluable) with disseminated breast cancer were treated with a combination of 5-fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM)." | 5.05 | 5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): an effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study. ( Cassidy, MJ; Cruicitt, M; Friedman, MA; Hendrickson, CG; Johnson, D; Kilbridge, T; Kohler, M; Marcus, FS; Resser, KJ; Reynolds, R; Yu, K, 1983) |
| "The Georgetown University Hospital experience in the treatment of advanced breast cancer using either a combination of doxorubicin (adriamycin) and vincristine (AV) or adriamycin and mitomycin-C (AM) is presented." | 5.05 | Treatment of advanced breast cancer with two doxorubicin-containing regimens. ( Byrne, PJ; Harris, MA; Oishi, S; Schein, PS; Schlesinger, C; Smith, FP; Ueno, W, 1984) |
| "The aim of this study was to compare the treatment efficacy of mitomycin-C plus tamoxifen (MT) to adriamycin, dibromodulcitol and tamoxifen (DAT) in previously treated patients with metastatic breast cancer." | 5.05 | A pilot study of mitomycin-C and tamoxifen (MT) versus dibromodulcitol, adriamycin, and tamoxifen (DAT). ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1982) |
| "We report a case of acute fatal respiratory failure following mitomycin and vinblastine administration in a patient with metastatic breast cancer." | 4.77 | Fatal acute respiratory failure following vinblastine and mitomycin administration for breast cancer. ( Ballen, KK; Weiss, ST, 1988) |
| "Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer." | 4.77 | Mitomycin C in advanced breast cancer: an update. ( Godfrey, TE, 1988) |
| "Mitomycin C is a chemotherapeutic agent active against breast cancer." | 4.77 | Mitomycin C in the chemotherapy of advanced breast cancer. ( Garewal, HS, 1988) |
| "Background The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (90Y) resin microspheres in liver metastatic breast cancer (LMBC) patients." | 3.96 | Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. ( Aarts, BM; Beets-Tan, RGH; Deroose, CMALO; Dresen, RC; Klompenhouwer, EG; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2020) |
| "Mitomycin C (MMC) is an anti-cancer drug used for the treatment of breast cancer with limited therapeutic index, extreme gastric adverse effects and bone marrow suppression." | 3.91 | LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An ( Aghaei, M; Aliomrani, M; Azizi, R; Sarrami, N; Varshosaz, J, 2019) |
| "The aim of this study was to determine the safety and efficacy of Mitomycin C (MMC) infusion in a large cohort of advanced liver metastatic breast cancer patients (LMBC) and to determine factors influencing overall survival (OS)." | 3.91 | Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. ( Aarts, BM; Beets-Tan, RGH; Dresen, RC; Klompenhouwer, EG; Laenen, A; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2019) |
| "The present study aimed to solubilize the antineoplastic agent, mitomycin C (MMC), in two nanoemulsions (NEs) consisting of different essential oils (ginger (Gi) and frankincense (Fr)) in order to examine their anticancer activities on the HeLa cervical cancer cells and MCF-7 breast cancer cells." | 3.88 | Cytotoxicity and apoptosis enhancement in breast and cervical cancer cells upon coadministration of mitomycin C and essential oils in nanoemulsion formulations. ( Al-Otaibi, WA; Alkhatib, MH; Wali, AN, 2018) |
| "Between November 2002 and January 2015, 14 patients with 29 unresectable pulmonary or mediastinal breast cancer metastases underwent transcatheter arterial chemoembolization using SAP-MS (50-100 μm) after injection of a combination of 2-4 types of anticancer drugs (eg, cisplatin [30 mg] + fluorouracil [500 mg], or epirubicin [40 mg] + mitomycin C [4 mg] + fluorouracil [500 mg])." | 3.85 | Transcatheter Arterial Chemoembolization with Spherical Embolic Agent in Patients with Pulmonary or Mediastinal Metastases from Breast Cancer. ( Hori, A; Hori, S; Kennoki, N; Yuki, T, 2017) |
| "The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine." | 3.83 | Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. ( Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG, 2016) |
| " The authors in this study provided evidence for this rational design by co-encapsulation of doxorubicin and mitomycin C within polymer-lipid hybrid nanoparticles (DMPLN) in a breast cancer model." | 3.83 | Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. ( Adissu, HA; Cai, P; Chen, K; Cheng, J; Li, J; Pang, KS; Rauth, AM; Wu, XY; Zhang, RX; Zhang, T, 2016) |
| " The current study investigated the potential of curcumin to reduce breast cancer stem cell (BCSC) population for sensitizing breast cancer cells to mitomycin C (MMC) both in vitro and in vivo." | 3.81 | Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells. ( Chen, Q; Huang, S; Lu, Y; Su, S; Ye, M; Zhang, H; Zhou, Q, 2015) |
| "In order to explore the synergistic mechanisms of combinatorial treatment using curcumin and mitomycin C (MMC) for breast cancer, MCF-7 breast cancer xenografts were conducted to observe the synergistic effect of combinatorial treatment using curcumin and MMC at various dosages." | 3.80 | Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. ( Chen, QL; Du, J; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhou, QM, 2014) |
| "In breast cancer, a significant decrease in riboflavin (RF) serum levels and increase in RF carrier protein occurs, indicating a potential role of RF in disease progression." | 3.79 | Riboflavin-targeted polymer conjugates for breast tumor delivery. ( Avaritt, BR; Bareford, LM; Ghandehari, H; Nan, A; Swaan, PW, 2013) |
| " TP53 mutations, in particular those affecting the L2/L3 domains, are associated with resistance to anthracycline or mitomycin treatment in breast cancer patients." | 3.79 | Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. ( Berge, EO; Huun, J; Knappskog, S; Lillehaug, JR; Lønning, PE, 2013) |
| " The tested 4g,h, 6a-h, 10 and 12-14 exhibited remarkable cytotoxicity activity against breast cancer cell line MCF-7 with higher activity than tamoxifen." | 3.78 | Synthesis and docking studies of novel antitumor benzimidazoles. ( Ali, MM; El Diwani, HI; Galal, SA; Kerwin, SM; Li, J; Omar, MA; Ramadan, RA; Shaker, YM; Tokuda, H, 2012) |
| "Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM)." | 3.78 | Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study. ( Aldabbagh, K; Fabbro, M; Jacot, W; Pouderoux, S; Poujol, S; Roca, L; Romieu, G, 2012) |
| "To investigate the efficacy of mitomycin C (MMC) in combination with curcumin in suppressing human breast cancer in vitro and in vivo." | 3.77 | Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. ( Liu, XJ; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhou, QM, 2011) |
| "The aim of this retrospective study was to evaluate the activity and toxicity of a combined chemotherapy containing mitomycin, folinate, and 5-fluorouracil (MiFoFU) in patients with advanced metastatic breast cancer and reduced performance status, ie, elderly patients or heavily pretreated patients." | 3.74 | Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis. ( Bruckner, T; Eichbaum, MH; Gast, AS; Schneeweiss, A; Sohn, C, 2007) |
| "In the treatment of extensive liver metastasis of breast cancer (LMBC), locally administered Mitomycin C (MMC) to the liver might be an effective approach with limited toxicity." | 3.74 | Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer. ( Demey, W; Heye, S; Maes, T; Maleux, G; Neven, P; Paridaens, R; Van Oosterom, AT; Wildiers, H, 2008) |
| "The combination of doxorubicin and mitomycin C has been shown previously to result in supra-additive tumor cell killing in vitro in both murine and human breast cancer cells and in vivo against murine breast cancer cells." | 3.74 | On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. ( O'Brien, PJ; Rauth, AM; Shuhendler, AJ; Wu, XY, 2007) |
| " A total of 21 genetic variants were studied in 35 breast cancer patients treated with 5-FluoroUracil, mitomycin (FUMI) and in a similar cohort of 90 doxorubicin treated breast cancer patients." | 3.74 | Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. ( Alnaes, GI; Børresen-Dale, AL; Hihn, B; Kristensen, VN; Liestøl, K; Lingjaerde, OC; Lønning, PE; Nordgard, SH; Sørlie, T; Tsalenko, A, 2008) |
| "Thirty-five patients with locally advanced breast cancer were investigated for TP53 mutations before receiving combination chemotherapy with 5-fluorouracil (1000 mg/m(2) on days 1 and 2) and mitomycin (6 mg/m(2) on day 2), administered every 3 weeks for 2-10 cycles in the neoadjuvant setting." | 3.72 | TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. ( Aas, T; Akslen, LA; Anker, G; Børresen-Dale, AL; Geisler, J; Geisler, S; Johnsen, H; Lønning, PE, 2003) |
| " We investigated p21 and p21B for mutations and epigenetic silencing in locally advanced breast cancers treated with doxorubicin or 5-fluorouracil/mitomycin and correlated our findings with treatment response and TP53 status." | 3.72 | Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. ( Leirvaag, B; Lillehaug, JR; Lønning, PE; Staalesen, V, 2004) |
| " To assess DNA repair for breast cancer susceptibility, we developed a modified HCR assay using a plasmid containing a firefly luciferase gene damaged by mitomycin C (MMC), which forms interstrand cross-link (ICL) adducts." | 3.72 | Repair of mitomycin C cross-linked DNA in mammalian cells measured by a host cell reactivation assay. ( Ahn, B; Kang, D; Kim, H; Wei, Q, 2004) |
| " To test the absolute requirement for caspase-3, we examined mitomycin C (MMC)-induced apoptosis in the caspase-3 deficient human breast cancer cell line MCF-7." | 3.71 | Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. ( Betticher, DC; Borner, MM; Pirnia, F; Schneider, E, 2002) |
| "A 50-year-old woman treated for breast cancer with mitomycin C developed severe hypertension, followed by deep coma 3 days later." | 3.71 | Hemolytic uremic syndrome with intracranial hemorrhage following mitomycin C administration. ( Katayama, Y; Kitamura, H; Komaba, Y; Nishiyama, Y, 2001) |
| "We have investigated the effects of chemotherapeutic agents such as adriamycin (ADR), camptothecin (CPT), mitomycin-C (MYC-C) and methotrexate (MTX) on the regulation of expression of the tumor susceptibility genes (BRCA1 and BRCA2), and the association of cell cycle progression in human breast cancer and normal breast epithelial cells." | 3.71 | Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells. ( Ciftci, K; Su, J, 2002) |
| "Fourty-six patients (41 evaluable) were treated in second line chemotherapy of metastatic breast cancer (MBC) by an association of mitomycin (M), vinorelbine (V) (M 8 mg/m2 D1, V 25 mg/m2 D1 and DI 8 every 4 weeks)." | 3.70 | [Mitomycin-vinorelbine combination as second-line chemotherapy in metastatic cancer of the breast]. ( Berlie, J; Bouchada, M; Bourgeois, H; Cvitkovic, F; Girard, M; Goupil, A; Janvier, M; Rouëssé, J; Soulie, P; Tubiana-Hulin, M; Turpin, F; Volters, A, 1998) |
| " We report the case history of a patient with myelodyspasia occurring after neoadjuvant methotrexate, mitoxantrone and mitomycin C (triple M) chemotherapy with subsequent radiotherapy for locally advanced breast cancer." | 3.70 | Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy. ( Lowdell, CP; Partridge, SE, 1999) |
| "Centchroman (CC), a non-steroidal oral contraceptive and a candidate drug for breast cancer, has been reported to exhibit partial to complete remission of lesions in 40." | 3.70 | Antimutagenic effects of centchroman--a contraceptive and a candidate drug for breast cancer in multiple mutational assays. ( Giri, AK; Hsie, AW; Mukhopadhyay, A; Ray, S; Sun, J, 1999) |
| "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2." | 3.70 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000) |
| "Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years." | 3.70 | Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000) |
| "Following upon earlier work the response of MCF-7 breast cancer cells to mitomycin C, a known genotoxicant, was examined." | 3.69 | A study of induced genotoxicity in MCF-7 cells. ( Bland, KI; Mark, HF; Naram, R; Santoro, K, 1995) |
| "Paclitaxel (BMS-181339: Taxol) is a promising agent against previously treated breast cancer." | 3.69 | Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. ( Asanuma, F; Hoshiya, Y; Kitajima, M; Koh, JI; Kubota, T; Matsuzaki, SW; Watanabe, M; Yamada, Y, 1997) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 3.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "Mitomycin C (MIT-C) is one of the most potent antineoplastic agents used for the treatment of breast cancer and a wide variety of malignant tumors." | 3.68 | In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines. ( Clarke, R; Ghiorghis, A; Talebian, A, 1992) |
| "Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks." | 3.68 | Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. ( Campora, E; Gardin, G; Giudici, S; Merlini, L; Miglietta, L; Naso, C; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1992) |
| "A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer." | 3.68 | Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. ( D'Alessandro, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A, 1991) |
| "35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF)." | 3.68 | [Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. ( Chronides, A; Diedrich, K; Krebs, D; Mallmann, P; Wagner, U; Werner, A, 1991) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | 3.68 | [5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "Prognostic factors were identified in a group of 210 patients with inflammatory breast carcinoma (IBC) treated at Institut Gustave Roussy from 1976-1985 with three successive induction protocols: Group A (n = 91), 1976-1980, doxorubicin, vincristine, methotrexate (AVM); Group B (n = 79), 1980-1982, doxorubicin, vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (AVCMF); Group C (n = 40), 1983-1985, AVCMF." | 3.68 | Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. ( Friedman, S; Mouriesse, H; Rouëssé, J; Sarrazin, D; Spielmann, M, 1990) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "Adriamycin and mitomycin C in combination have been tested in the treatment of advanced breast cancer." | 3.67 | Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer. ( Amiel, SA; Earl, HM; Knight, RK; Rubens, RD; Stewart, JF, 1984) |
| "The influence of family history, irradiation and anti-cancer drug (Mitomycin C) on the occurrence of multiple primary neoplasms was analysed using the person-year method in 1359 Japanese breast carcinoma patients." | 3.67 | [Influence of family history, irradiation and anti-cancer drug (mitomycin C) on the occurrence of multiple primary neoplasms in breast carcinoma patients]. ( Fukami, A; Kasumi, F; Kuno, K; Sakamoto, G; Sugano, H; Yoshimoto, M, 1984) |
| "Twenty-six patients with advanced breast cancer, (12 previously treated with adriamycin-containing regimens, 14 not exposed to adriamycin because of poor cardiac performance), were treated with combination chemotherapy including mitomycin C plus 5-fluorouracil." | 3.67 | Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients. ( Ardizzoni, A; Conte, PF; Pronzato, P; Rosso, R, 1984) |
| "A 49 year old woman treated for metastatic adenocarcinoma of the breast suddenly developed the symptoms of acute pulmonary edema 90 minutes after infusion of mitomycin C/vinblastine." | 3.67 | [Acute dyspnea following intravenous administration of vinblastine/mitomycin C]. ( Gattiker, HH; Lagler, U, 1989) |
| "A combination of mitomycin C and vinblastine was administered as salvage treatment in 44 patients with heavily pretreated refractory breast cancer." | 3.67 | Mitomycin C and vinblastine in advanced refractory breast cancer. ( Bonadonna, G; Brambilla, C; Ferrari, L; Zambetti, M, 1989) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 3.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i." | 3.67 | Etoposide and mitomycin-C in pretreated metastatic breast cancer. ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989) |
| "A 54-year-old woman with metastatic breast cancer developed veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin." | 3.67 | Veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin. ( Craft, PS; Pembrey, RG, 1987) |
| "In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied." | 3.67 | [Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985) |
| " Following our former report in which the combination effects of mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) were clarified, combined applications of 4 drugs, vindesine (VDS), methotrexate (MTX), cisplatin (CDDP) and 5'-DFUR against 3 lines of human breast cancer (H-62, H-31, H-71), and one line each of gastric cancer (H-55) and colon cancer (H-110) xenografted into nude mice were evaluated in comparison with CAF (cyclophosphamide, adriamycin and 5-FU) therapy which is commonly used for breast cancer." | 3.67 | [Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T, 1987) |
| " In our previous studies with human gastrointestinal and breast cancers xenografted into nude mice, combination therapy with mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) [I] or cisplatin (CDDP), vindesine (VDS) and 5'-DFUR [II] produced higher response rates than single-agent therapy with any one of these drugs." | 3.67 | [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987) |
| "Forty-nine patients with liver metastases of breast cancer were treated with arterial infusion involving simultaneous use of adriamycin: 30-50 mg and mitomycin C: 10-20 mg through the hepatic artery by Seldinger catheter." | 3.67 | [Arterial infusion of combination chemotherapy consisting of adriamycin and mitomycin C for liver metastases of breast cancer]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Tada, A; Ueno, K; Yamazaki, H, 1986) |
| "Fifty-seven patients with advanced breast cancer were treated with a combination of 5-fluorouracil and mitomycin C (FuMi)." | 3.67 | 5-Fluorouracil and mitomycin C in advanced breast cancer. ( Aspegren, K; Landberg, T, 1986) |
| " Fifty-seven patients with postoperative breast cancer received MMF (mitomycin, methotrexate, futraful therapy with SNMC and 60 were given MMF alone." | 3.67 | [Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)]. ( Akimoto, M; Iwasaki, H; Kasai, M; Kimura, M; Matano, S; Nakajima, Y; Sawano, A, 1986) |
| "Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active." | 3.67 | Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. ( Dees, A; Stoter, G; van Putten, WL; Verweij, J, 1987) |
| "The effect of preoperative intra-arterial infusion of mitomycin C, 5-fluorouracil (5-FU) and adriamycin (ADM) were studied in seven patients with locally advanced breast cancer, including five inflammatory carcinomas, and a patient with stromal sarcoma of the breast." | 3.67 | [Preoperative intra-arterial infusion chemotherapy in locally advanced primary breast cancer-tissue concentrations of 5-fluorouracil and adriamycin, and the histological evaluation]. ( Ikoma, M; Ishikawa, H; Kasahara, M; Murayama, N; Shimada, A; Takenaka, Y; Watanabe, M; Yoshida, H, 1988) |
| "The influence of family history of cancer, radiation therapy and anticancer drug therapy (mitomycin C) on the occurrence of multiple primary neoplasms, following treatment of a first primary cancer of the breast, was analyzed by the person-year method in 1,359 patients, in Japan." | 3.67 | The influence of family history of cancer, irradiation and anticancer medication (mitomycin C), on the occurrence of multiple primary neoplasms with breast cancer--statistical analysis by the person-year method. ( Fukami, A; Kajitani, T; Kasumi, F; Nishi, M; Sakamoto, G; Yoshimoto, M, 1985) |
| "Twenty-seven patients with metastatic adenocarcinoma of the breast refractory to other chemotherapy were treated with mitomycin-C plus metronidazole." | 3.67 | Mitomycin-C plus metronidazole in advanced carcinoma of the breast. ( Crook, AF; Heringer, R; Lefebvre, B; Maroun, JA; Stewart, DJ, 1985) |
| "Forty-six patients with recurrent metastatic breast cancer were treated with a combination chemotherapy including doxorubicin and mitomycin C." | 3.67 | Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. ( Brambilla, MC; Comazzi, R; Genitoni, V; Guindani, A; Lacaita, G; Villani, F; Volonterio, A, 1985) |
| "Eight previously irradiated breast cancer patients with local recurrences were treated with intra-arterial infusions of 8 mg/m2 mitomycin C given at 3-week intervals." | 3.67 | Intra-arterial infusion of mitomycin C in treatment of breast cancer: occurrence of skin necrosis in irradiated patients. ( Fodstad, O; Gundersen, S; Hager, B; Kvalheim, G, 1985) |
| "Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks." | 3.67 | Mitomycin C and vinblastine in the treatment of advanced breast cancer. ( Knight, RK; Radford, JA; Rubens, RD, 1985) |
| "43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i." | 3.66 | Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | 3.66 | [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "Mitomycin C together with either vindesine or vinblastine was given to 48 patients with previously treated advanced breast cancer." | 3.66 | Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. ( Brooks, RJ; Garewal, HS; Jones, SE; Miller, TP, 1983) |
| "The clinical efficacy of two combination chemotherapies, "CAF" (cyclophosphamide, adriamycin, fluorouracil) and "CMcF" (cyclophosphamide, mitomycin C, fluorouracil) were evaluated on the patients with disseminated breast cancer." | 3.66 | [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1983) |
| "In a Phase II study, 50 patients with advanced breast cancer were treated with a combination of 5-fluorouracil (1000 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen)." | 3.66 | A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. ( Bjelkengren, G; Hallsten, L; Mattsson, W; von Eyben, F, 1982) |
| "One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks." | 3.66 | [Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]. ( Brunet, R; Bui, BN; Chauvergne, J; Durand, M; Hoerni, B; Mauriac, L, 1981) |
| "Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin." | 3.66 | Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report. ( Oster, MW; Park, Y, 1983) |
| "Treatment with mitomycin-C only showed median and mean survival times of 13." | 2.75 | Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. ( Eichler, K; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S, 2010) |
| "Overall, 77." | 2.72 | Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | 2.70 | Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| "For the purpose of local control and breast conservation, intraarterial infusion chemotherapy combined with radiotherapy has been indicated in patients with locally advanced breast cancer both in primary and recurrent cases." | 2.68 | [Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy]. ( Kazawa, N; Kobayashi, K; Kono, K; Kuroda, Y; Maetani, Y; Murakami, M; Okamoto, Y; Sai, H; Sano, A; Sasaki, R; Yoden, E, 1997) |
| " QDBS syndrome is somehow related to immuno-deficiency and blood hypercoagulability, the method of Yiqi Huoxue (YQHX) which used to be combined with chemotherapy could not only reduce the toxic-side effects of chemotherapy, but also improve the cellular immune function and hemorheology." | 2.67 | [Studies of guben quyu No I combined with chemotherapy in treating cancer]. ( Peng, XM; Rao, XQ; Yu, RC, 1994) |
| "84 patients with large operable breast cancer have been treated with primary medical chemotherapy rather than mastectomy in three sequential studies." | 2.67 | Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. ( Baum, M; Jones, AL; McKinna, JA; O'Brien, ME; Sacks, N; Smith, IE, 1993) |
| "Patients with advanced breast cancer were randomised to 3M (mitozantrone 6." | 2.67 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. ( Barton, C; Bliss, JM; Bower, M; Coombes, RC; Ford, HT; Gazet, JC; Law, M; Stein, RC, 1992) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 2.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "Sixty-seven breast cancer patients with malignant pleural effusions underwent their first thoracentesis between 1980 and 1990 at 13 institutes in Kyoto and Shiga Prefectures." | 2.67 | [Intrapleural treatment of breast cancer patients with pleural effusions: an analysis of 13 institutes in Kyoto and Shiga Prefectures. Kyoto and Shiga Breast Cancer Study Group]. ( Hori, T; Kan, N; Kato, H; Kodama, H; Kudo, N; Mukaihara, S; Ogawa, H; Ohsumi, K; Takenaka, A; Yasumura, T, 1992) |
| "Prognostic factors of primary breast cancer was discussed." | 2.66 | [Systemic adjuvant therapy in patients with operable breast cancer]. ( Hisamatsu, K; Nomura, Y; Tashiro, H, 1989) |
| "It was shown that after the breast cancer became refractory to tamoxifen, the major endocrine ablation therapy was effective particularly in ER (+) cancers, irrespective of the response to the antiestrogen." | 2.65 | [Present status of endocrine therapy of breast cancer: a surgeon's view]. ( Nomura, Y, 1984) |
| "The effect of fibrinolytic agents, Tissue Culture Urokinase (TCUK) and Urinary Urokinase (UUK), was investigated in a total of 146 patients with gastric cancer, pulmonary cancer or breast cancer who received various anti-cancer agents, mainly MMC, in combination with the fibrinolytic agents." | 2.65 | [Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]. ( Yamamoto, M, 1982) |
| "Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma." | 2.46 | Mitomycin C in patients with gynecological malignancies. ( Beyer, U; Fasching, PA; Kahmann, L; Lux, MP; Mehlhorn, G; Strnad, V; Thiel, FC, 2010) |
| "In five heavily pretreated women with breast cancer, one patient had a complete response, one patient had a partial response, and one patient had stable disease." | 2.42 | Rationale for mitomycin and irinotecan use in advanced breast cancer. ( Shapiro, CL; Xu, Y, 2003) |
| "Secondary spontaneous pneumothorax (SSP) is a rare complication of chemotherapy for pulmonary metastases and to the best of our knowledge, only 28 cases have been described, most of which occurred in patients with osteosarcoma or germ cell tumors." | 2.41 | Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case. ( Ansaloni, L; Bazzocchi, R; Bini, A; Grazia, M; Stella, F; Zompatori, M, 2000) |
| "The main therapy for primary breast cancer is not surgery, but a systemic therapy involving administration of cytotoxic chemotherapy or the use of ablative or additive endocrine therapy to control disseminated micrometastasis." | 2.40 | [Benefits of adjuvant chemotherapy for breast cancer]. ( Inaji, H; Koyama, H; Motomura, K; Noguchi, S, 1997) |
| " The issues under investigation include best chemotherapy dosage and duration, identification of risk factors and the role of preoperative chemotherapy." | 2.39 | ["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan]. ( Ikeda, T, 1994) |
| "A 24-year-old patient who developed breast cancer 16 years after chemotherapy for osteosarcoma is presented." | 2.38 | Breast cancer developing after chemotherapy for osteosarcoma: a case report. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Ogata, Y; Ozawa, I; Sekiguchi, C; Shimamura, K; Shimizu, H, 1991) |
| "Mitomycin-C is an effective antitumor agent in breast cancer and should be carefully incorporated in the therapeutic strategy of this disease." | 2.37 | Mitomycin-C in breast cancer. ( Hortobagyi, GN, 1985) |
| "This is even lower in triple-negative breast cancer (TNBC) patients with concomitant lung metastases." | 1.51 | Isolated thoracic perfusion in lung metastases from breast cancer: a retrospective observational study. ( Aigner, K; Clementi, M; Deraco, M; Fiorentini, G; Guadagni, S; Masedu, F; Ricevuto, E; Zoras, O, 2019) |
| "HAIC offers a safe and effective salvage treatment strategy in heavily pretreated patients with LMBC and no further treatment options." | 1.46 | Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters. ( Bogner, S; Peis, MW; Reinboldt, MP; Schuler, M; Tewes, M; Theysohn, JM; Welt, A, 2017) |
| "Treatment with mitomycin C decreased MRP expression at high concentrations and hyperthermia intensified these effects." | 1.39 | The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels. ( Franke, K; Hilger, I; Kaiser, WA; Kettering, M; Lange, K, 2013) |
| "Among 148 breast cancer samples analyzed by MLPA, four samples harbored intragenic deletions/duplications: Thus, exons 1-2 were deleted in two tumors and exons 21-23 in one tumor, while one sample harbored duplication of exons 18-23." | 1.37 | Alterations of the retinoblastoma gene in metastatic breast cancer. ( Berge, EO; Knappskog, S; Lillehaug, JR; Lønning, PE, 2011) |
| "Functional antagonism of hGH in the endometrial carcinoma cell line RL95-2, which endogenously expresses hGH, significantly increased the sensitivity of these cells to MMC-induced DNA damage and cell death." | 1.37 | Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. ( Bougen, NM; Chen, H; Lobie, PE; Perry, JK; Yang, T, 2011) |
| "and compound 7c exhibit good anticancer activity against ovary (IGR-OV-1), breast (MCF-7) and CNS(SF-295) human cancer cell lines." | 1.36 | Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. ( Agrawal, SK; Rani, R; Roy, P; Saxena, AK; Singh, J; Sondhi, SM, 2010) |
| " Under the diagnosis of cardiac tamponade, we treated her with pericardial drainage and systemic chemotherapy (intravenous dosage of trastuzumab and vinorelbine: VNR), and then pericardial effusion disappeared." | 1.36 | [A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillations of OK-432 and mitomycin C]. ( Fujita, M; Matsuura, O; Morohashi, H; Morohashi, S; Nishimura, A; Yakoshi, Y; Yamada, K; Yonaiyama, S, 2010) |
| "A recurrent breast cancer patient received high-dose chemotherapy, a transplant of multidrug resistance 1 (MDR1)-transduced cells and four different protocols of post-transplantation chemotherapy." | 1.36 | In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. ( Aiba, K; Hatake, K; Hosoyama, H; Ito, Y; Katayama, K; Mitsuhashi, J; Noguchi, K; Sugimoto, Y; Takahashi, S; Tsukahara, S, 2010) |
| "We report on a 45-year-old breast cancer patient with disseminated hepatic metastases." | 1.36 | Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). ( Eichbaum, MH; Hauser, N; Hohl, MK; Sohn, C; Stoiber, B; Stoiber, N, 2010) |
| "For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0." | 1.35 | Platinum-based chemotherapy in triple-negative breast cancer. ( Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G, 2008) |
| "Hereditary cases of breast and ovarian cancer are often attributed to germ-line mutations of the BRCA1 tumor suppressor gene." | 1.35 | E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. ( Baer, R; Cheng, JT; Jasin, M; Lokshin, M; Ludwig, T; Modi, AP; Reid, LJ; Shakya, R, 2008) |
| "Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)." | 1.35 | Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009) |
| "Pure primary squamous cell carcinoma (SCC) of the breast is rare and difficult to treat." | 1.35 | Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy. ( Bhatt, L; Fernando, I, 2009) |
| "For 14 patients with metastatic breast cancer, MR imaging studies before and after TACE were evaluated." | 1.34 | Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. ( Buijs, M; Georgiades, CS; Geschwind, JF; Hong, K; Kamel, IR; Vossen, JA, 2007) |
| "Recent studies on familial breast cancer clusters revealed chromosomal rearrangements and higher rates of sister chromatid exchanges also in heterozygous BRCA2 mutation carriers." | 1.33 | Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair. ( Arnold, K; Edler, L; Frerk, K; Kim, MK; Savelyeva, L; Schmezer, P; Wiedemeyer, R, 2006) |
| "Using two human breast cancer cell lines, MDA-MB-231 and BT-474, the antitumor effects of a combination of antisense ODN and anticancer drugs, including mitomycin C (MMC), adriamycin (ADM), paclitaxel (TXL), and docetaxel (TXT) was evaluated." | 1.32 | Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. ( Emi, M; Inoue, H; Kim, R; Tanabe, K; Toge, T; Uchida, Y, 2003) |
| "Pathologic response of breast cancer to chemotherapy has a great prognostic importance." | 1.32 | Glutathion S transferase pi indicates chemotherapy resistance in breast cancer. ( Gong, C; Hamar, P; Hu, X; Jia, W; Song, E; Su, F, 2003) |
| "There is evidence to suggest that the breast cancer predisposing gene, BRCA1, is involved in cell cycle control and the response to damage but mouse brca1+/- heterozygotes have no distinctive phenotype." | 1.32 | Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. ( Eccles, D; Eeles, R; Latham, H; McMillan, TJ; Peacock, JH; Shorrocks, J; Tobi, SE, 2004) |
| "In p53 wild-type MCF-7 breast carcinoma cells, the cyclin-dependent kinase inhibitor protein p21/WAF1 was markedly induced after the treatment with MMC alone, although this response was significantly delayed from the time of MMC treatment." | 1.31 | UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. ( Akinaga, S; Akiyama, T; Eastman, A; Shimizu, M; Sugiyama, K; Takahashi, R; Tamaoki, T; Yamaguchi, K, 2000) |
| "Mitomycin C (MMC) is a DNA cross-linking agent that has been used in cancer chemotherapy for >20 years." | 1.31 | Detection of mitomycin C-DNA adducts in human breast cancer cells grown in culture, as xenografted tumors in nude mice, and in biopsies of human breast cancer patient tumors as determined by (32)P-postlabeling. ( Hamilton, JW; Mustra, DJ; Warren, AJ, 2001) |
| "TAIC for locally advanced breast cancer is useful in reducing tumor size and achieving down-staging in a relatively short period, leading to an expanded surgical indication." | 1.31 | Preoperative transcatheter arterial infusion chemotherapy for locally advanced breast cancer (stage IIIb) for down-staging and increase of resectability. ( Kawarada, Y; Kitagawa, K; Matsumura, K; Nakatsuka, A; Takeda, K; Tanaka, N; Yamakado, K, 2002) |
| "Eleven patients with T4 breast cancer received induction intraarterial chemotherapy (IACT) as the first step in multidisciplinary therapy." | 1.30 | Induction intraarterial chemotherapy for T4 breast cancer through an implantable port-catheter system. ( Chang, HT; Mok, KT; Tzeng, WS, 1997) |
| "We diagnosed the patient as recurrent breast cancer metastatic to liver, 14 years postoperatively." | 1.30 | [Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report]. ( Arai, K; Imai, R; Ito, K; Kojima, K; Muro, H; Nakagami, K; Nakajima, N; Nishimura, K; Onogawa, S; Suzuki, M; Tohyama, K; Umeda, Y, 1997) |
| " CGP 69846A, in combination with cisplatin, showed superadditive antitumor effects against PC3 human prostate carcinomas with tumor cures, and in combination with mitomycin C, superadditive antitumor effects of CGP 69846A with tumor cures against NCI-H460 large cell lung carcinoma were found." | 1.30 | Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. ( Fabbro, D; Geiger, T; Monia, BP; Müller, M, 1997) |
| "Mitomycin C pretreatment also significantly increased the sensitivity of cancer cells to subsequent killing by the P-glycoprotein substrate doxorubicin, decreasing the ED50 by 5- to 10-fold." | 1.30 | Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. ( Blaxall, JR; Hamilton, JW; Ihnat, MA; La Ronde, N; Lariviere, JP; Pierre, KM; Turpie, BW; Warren, AJ, 1997) |
| "For these studies, MKN-74 gastric cancer cells and MDA-MB-468 breast cancer cells were exposed to either no drug, 1 microgram/ml MMC alone, 300 nM flavopiridol alone, or a combination of chemotherapy with flavopiridol for 24 h." | 1.30 | Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. ( Farsi, K; Kelsen, DP; Maslak, P; Schwartz, GK; Spriggs, D, 1997) |
| "In the survival analysis of early breast cancer patients, we have to estimate the contribution of second cancers to properly evaluate the effect of treatment." | 1.30 | Prognostic impact of second cancer on the survival of early breast cancer patients. ( Murakami, S; Nomura, Y; Takenaka, Y; Tsutsui, S, 1999) |
| "Primary breast cancer cell lines null for p53 protein were resistant to MMC." | 1.29 | The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. ( Meikrantz, W; Sager, R; Schlegel, R; Xu, C, 1995) |
| "Patients with early breast cancer (T1/T2) had a complete clinical resolution in 41% (16/39) of cases after MMM and in 20% (7/35) of cases following endocrine therapy compared with 14% (2/14) advanced tumours (T3/T4) following MMM and (0/12) following endocrine therapy." | 1.29 | Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. ( Coombes, RC; Corbishley, C; Ford, HT; Gazet, JC; Griffin, M; Lowndes, S; Makinde, V; Quilliam, J; Sutcliffe, R, 1996) |
| "Skin phototoxicity, tested by using a standardised illumination of skin patches on the back, lasted maximally 3 weeks." | 1.29 | Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. ( Baas, P; Beynen, JH; Meyer, M; Oppelaar, H; Stewart, FA; van Geel, IP; van Zandwijk, N, 1996) |
| "We experienced 522 patients with breast carcinoma and 14 cases (2." | 1.29 | [A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy]. ( Matsumine, T; Matsumoto, J; Minami, T; Takami, M; Takanishi, K, 1996) |
| "We treated this locally advanced breast cancer by intra-arterial infusion chemotherapy." | 1.28 | [Successfully treated locally advanced breast cancer by intra-arterial infusion chemotherapy: a case report]. ( Akiyama, H; Nakazawa, H; Suzuki, N, 1992) |
| "We reported a case of locally advanced breast cancer who was cannulated into the right internal thoracic artery through the right femoral artery by Seldinger's method for intra-arterial chemotherapy and obtained good results." | 1.28 | [A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF]. ( Miura, T; Murata, M; Seki, M; Shinohara, K; Takagi, S; Tezuka, T, 1992) |
| "Three human breast carcinoma xenografts, MCF-7, R-27 and T-61 serially transplanted into nude mice were treated with mitomycin C (MMC) alone, KM2210 (estra-1, 3, 5(10)-triene-3, 17 beta-diol, 3 benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acetate) alone and KM2210 followed by MMC." | 1.28 | [Enhancement of antitumor activity of mitomycin C against human breast carcinoma xenografts by pretreatment with KM 2210]. ( Arisawa, Y; Fujita, S; Inoue, S; Ishibiki, K; Josui, K; Kubota, T; Kuzuoka, M; Oka, S; Suto, A; Yamamoto, T, 1990) |
| "The 36 patients with breast cancer were divided into two groups." | 1.28 | [The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer]. ( Hagiwara, M; Kanasugi, K; Komoriyama, H; Morikubo, M; Oikawa, H; Satoh, T; Tsukikawa, S; Yamaguchi, S, 1990) |
| " These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination." | 1.28 | The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer. ( Abe, R; Akiyoshi, T; Arinaga, S; Inoue, H; Karimine, N; Matsuoka, H; Nagamatsu, M; Nanbara, S; Takamuku, K; Watanabe, D, 1990) |
| "Mitomycin C is an alkylating agent used in cancer chemotherapy that shows some specificity towards hypoxic cells." | 1.28 | Activation of mitomycin C by NADPH:cytochrome P-450 reductase. ( Bartoszek, A; Beggs, JD; Bligh, HF; Hickson, ID; Kasper, CB; Robson, CN; Wolf, CR, 1990) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | 1.28 | [Clinical efficacy of ifosfamide for liver metastasis of breast cancer]. ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| " Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma." | 1.28 | [Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer]. ( Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990) |
| "Eight lines of human breast tumors implanted in nude mice were treated with various antitumor agents at two different doses, maximum tolerated doses (MTD) and rational doses (RD) that were pharmacokinetically equivalent to the clinical doses; the response rates to both doses were compared." | 1.28 | Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. ( Inaba, M; Kobayashi, T; Maruo, K; Nomura, T; Ohnishi, Y; Sakurai, Y; Tashiro, T; Ueyama, Y, 1989) |
| "A patient with breast cancer was treated with adoptive immunotherapy of CTL because she had severe side effect from antineoplastics ." | 1.28 | [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers]. ( Kitsukawa, K, 1989) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | 1.27 | Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| "Especially in liver metastasis of the breast cancer, MMC-m." | 1.27 | [Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer]. ( Itoh, J; Katoh, T; Nakagawa, H; Sasaki, H; Takahashi, T, 1983) |
| "In 41 cases of primary breast cancer preoperative treatment was performed using 2 methods consisting CPA + FT-207 (5-FUDS) (for Group I) and CPA + FT-207 (5-FUDS) + MMC (for Group II) to determine clinical and histological efficacies." | 1.27 | [Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC]. ( Andoh, H; Fujii, Y; Gotoh, M; Hagiwara, H; Hara, Y; Kataoka, J; Kobayashi, T; Komuro, K; Nagasaki, Y; Nagayama, A; Nakamura, K; Nakamura, R, 1983) |
| "For patients with breast cancer who had received extensive prior therapy, 3 mg/m2/day for 5 days repeated every 6-8 weeks were well-tolerated doses; and for patients with gastrointestinal cancer, the maximum-tolerated dose was 4 mg/m2/day." | 1.27 | A phase I-II study of continuous 5-day infusion mitomycin-C. ( Bedikian, A; Blumenschein, G; Hortobagyi, G; Valdivieso, M; Yap, HY, 1983) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| "Mitomycin C (MMC) was combined with 2." | 1.27 | Combined cytotoxic and endocrine therapy for human breast carcinoma (Br-10) serially transplanted into nude mice. ( Abe, O; Asanuma, F; Enomoto, K; Ishibiki, K; Koh, J; Kubota, T; Kubouchi, K, 1984) |
| "As for the treatment of recurrent breast cancer, it is important to consider hormone receptor, lesion and age and to choose the effective mode of treatment for the first (recurrence of the) disease." | 1.27 | [An analysis of treatments of recurrent breast cancer in relation to the lesion]. ( Hirai, T; Iino, Y; Ishida, T; Izuo, M; Kawai, T; Ogawa, T; Suzuki, H; Yokoe, T, 1985) |
| "She died from general metastasis seven months after the radical mastectomy in spite of adjuvant immunochemotherapy." | 1.27 | [A case of bilateral metastatic breast carcinoma from gastric carcinoma]. ( Hanamura, N; Iida, F; Kasuga, Y; Katsuyama, T; Oota, H; Senga, O; Tsuchiya, S, 1986) |
| "A case of brain metastasis in ovarian cancer is reported." | 1.27 | [Metastatic brain tumor after chemotherapy of ovarian cancer]. ( Chen, JT; Fujimoto, I; Fukuda, K; Hasumi, K; Masubuchi, K; Sakamoto, A; Yamauchi, K, 1987) |
| "A 51-year-old woman with breast cancer metastatic to the pleura was treated with intrapleural instillation of adriamycin after thoracentesis, and systemic administration of FEMP, with complete response for more than 11 months." | 1.27 | [A case of breast cancer with pleural metastasis responding to administration of intrapleural adriamycin and systemic chemotherapy with FEMP]. ( Adachi, Y; Bada, K; Denno, R; Kohno, Y; Nishizawa, F; Ogasahara, K; Ohbayashi, M; Takahashi, J; Takeda, R; Yoshimura, T, 1987) |
| "Twenty-eight patients with inflammatory breast cancer were treated with combined modality therapy consisting of (1) intraarterial infusion chemotherapy (IA chemotherapy) through the internal thoracic artery and subclavian artery, (2) surgical ablation, (3) extended radical mastectomy, and (4) adjuvant chemotherapy in that order." | 1.27 | Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients. ( Koyama, H; Miyauchi, K; Nishizawa, Y; Noguchi, S; Terasawa, T, 1988) |
| "Four human breast carcinoma strains serially transplanted into nude mice were used for the experimental chemotherapy and combination chemoendocrine therapy." | 1.27 | [Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice]. ( Koh, J, 1988) |
| "Primary chemotherapy of brain metastases yielded responses in 27 of 52 patients (52%) treated with Cytoxan (cyclophosphamide) (C), 5-fluorouracil (F) and prednisone (P); 19 of 35 (54%) receiving CFP-methotrexate (M) and vincristine (V); 3 of 7 (43%) treated with MVP, and 1 of 6 (17%) receiving Cytoxan plus Adriamycin (doxorubicin) (CA)." | 1.27 | Chemotherapy induces regression of brain metastases in breast carcinoma. ( Lane, WW; Nemoto, T; Rosner, D, 1986) |
| "The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery." | 1.26 | [Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)]. ( Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 128 (32.16) | 18.7374 |
| 1990's | 141 (35.43) | 18.2507 |
| 2000's | 74 (18.59) | 29.6817 |
| 2010's | 54 (13.57) | 24.3611 |
| 2020's | 1 (0.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kunz, KR | 1 |
| Iyengar, BS | 1 |
| Dorr, RT | 1 |
| Alberts, DS | 1 |
| Remers, WA | 1 |
| Iwasa, K | 1 |
| Moriyasu, M | 1 |
| Yamori, T | 1 |
| Turuo, T | 1 |
| Lee, DU | 1 |
| Wiegrebe, W | 1 |
| McKee, ML | 1 |
| Kerwin, SM | 2 |
| Kakadiya, R | 1 |
| Dong, H | 1 |
| Lee, PC | 1 |
| Kapuriya, N | 1 |
| Zhang, X | 2 |
| Chou, TC | 1 |
| Lee, TC | 1 |
| Kapuriya, K | 1 |
| Shah, A | 1 |
| Su, TL | 1 |
| Sondhi, SM | 1 |
| Rani, R | 1 |
| Singh, J | 1 |
| Roy, P | 1 |
| Agrawal, SK | 1 |
| Saxena, AK | 1 |
| Omar, MA | 1 |
| Shaker, YM | 1 |
| Galal, SA | 1 |
| Ali, MM | 1 |
| Li, J | 3 |
| Tokuda, H | 1 |
| Ramadan, RA | 1 |
| El Diwani, HI | 1 |
| Yu, X | 1 |
| Zhang, Q | 1 |
| Tian, L | 1 |
| Guo, Z | 1 |
| Liu, C | 1 |
| Chen, J | 1 |
| Ebrahim, W | 1 |
| Liu, Z | 1 |
| Proksch, P | 1 |
| Zou, K | 1 |
| Feng, W | 1 |
| Simpson, DA | 1 |
| Carvajal-Garcia, J | 1 |
| Price, BA | 1 |
| Kumar, RJ | 1 |
| Mose, LE | 1 |
| Wood, RD | 1 |
| Rashid, N | 1 |
| Purvis, JE | 1 |
| Parker, JS | 1 |
| Ramsden, DA | 1 |
| Gupta, GP | 1 |
| Aarts, BM | 2 |
| Klompenhouwer, EG | 2 |
| Dresen, RC | 2 |
| Deroose, CMALO | 1 |
| Beets-Tan, RGH | 2 |
| Punie, K | 2 |
| Neven, P | 3 |
| Wildiers, H | 3 |
| Maleux, G | 3 |
| Tewes, M | 1 |
| Peis, MW | 1 |
| Bogner, S | 1 |
| Theysohn, JM | 1 |
| Reinboldt, MP | 1 |
| Schuler, M | 1 |
| Welt, A | 1 |
| Kennoki, N | 1 |
| Hori, S | 1 |
| Yuki, T | 1 |
| Hori, A | 1 |
| Gayarre, J | 1 |
| Martín-Gimeno, P | 1 |
| Osorio, A | 1 |
| Paumard, B | 1 |
| Barroso, A | 1 |
| Fernández, V | 1 |
| de la Hoya, M | 1 |
| Rojo, A | 1 |
| Caldés, T | 1 |
| Palacios, J | 1 |
| Urioste, M | 1 |
| Benítez, J | 1 |
| García, MJ | 1 |
| Razmi, M | 1 |
| Rabbani-Chadegani, A | 1 |
| Hashemi-Niasari, F | 1 |
| Ghadam, P | 1 |
| Al-Otaibi, WA | 2 |
| Alkhatib, MH | 2 |
| Wali, AN | 2 |
| Sotgia, F | 1 |
| Ozsvari, B | 1 |
| Fiorillo, M | 1 |
| De Francesco, EM | 1 |
| Bonuccelli, G | 1 |
| Lisanti, MP | 1 |
| Guadagni, S | 1 |
| Aigner, K | 1 |
| Zoras, O | 1 |
| Masedu, F | 1 |
| Fiorentini, G | 2 |
| Ricevuto, E | 1 |
| Deraco, M | 1 |
| Clementi, M | 1 |
| Varshosaz, J | 1 |
| Sarrami, N | 1 |
| Aghaei, M | 1 |
| Aliomrani, M | 1 |
| Azizi, R | 1 |
| Laenen, A | 1 |
| Farshid, P | 1 |
| Darvishi, A | 1 |
| Naguib, N | 1 |
| Bazrafshan, B | 1 |
| Paul, J | 1 |
| Mbalisike, E | 1 |
| Vogl, TJ | 4 |
| Bareford, LM | 1 |
| Avaritt, BR | 1 |
| Ghandehari, H | 1 |
| Nan, A | 1 |
| Swaan, PW | 1 |
| Cicek, D | 1 |
| Cobanoglu, B | 1 |
| Inci, R | 1 |
| Dertlioglu, SB | 1 |
| Kokcam, I | 1 |
| Elkiran, T | 1 |
| Zhao, L | 1 |
| Li, Y | 1 |
| He, M | 1 |
| Song, Z | 1 |
| Lin, S | 1 |
| Yu, Z | 1 |
| Bai, X | 1 |
| Wang, E | 1 |
| Wei, M | 1 |
| Zhou, QM | 2 |
| Chen, QL | 1 |
| Du, J | 1 |
| Wang, XF | 2 |
| Lu, YY | 2 |
| Zhang, H | 3 |
| Su, SB | 2 |
| Knappskog, S | 4 |
| Berge, EO | 3 |
| Chrisanthar, R | 2 |
| Geisler, S | 3 |
| Staalesen, V | 2 |
| Leirvaag, B | 3 |
| Yndestad, S | 1 |
| de Faveri, E | 1 |
| Karlsen, BO | 1 |
| Wedge, DC | 1 |
| Akslen, LA | 3 |
| Lilleng, PK | 1 |
| Løkkevik, E | 2 |
| Lundgren, S | 2 |
| Østenstad, B | 2 |
| Risberg, T | 2 |
| Mjaaland, I | 2 |
| Aas, T | 4 |
| Lønning, PE | 10 |
| Zhou, Q | 1 |
| Ye, M | 1 |
| Lu, Y | 1 |
| Chen, Q | 1 |
| Huang, S | 1 |
| Su, S | 1 |
| Rodríguez, A | 1 |
| Torres, L | 1 |
| Juárez, U | 1 |
| Sosa, D | 1 |
| Azpeitia, E | 1 |
| García-de Teresa, B | 1 |
| Cortés, E | 1 |
| Ortíz, R | 1 |
| Salazar, AM | 1 |
| Ostrosky-Wegman, P | 1 |
| Mendoza, L | 1 |
| Frías, S | 1 |
| Almstedt, K | 1 |
| Fasching, PA | 2 |
| Scharl, A | 1 |
| Rauh, C | 1 |
| Rack, B | 1 |
| Hein, A | 1 |
| Hack, CC | 1 |
| Bayer, CM | 1 |
| Jud, SM | 1 |
| Schrauder, MG | 1 |
| Beckmann, MW | 1 |
| Lux, MP | 2 |
| Zhang, RX | 1 |
| Cai, P | 2 |
| Zhang, T | 1 |
| Chen, K | 1 |
| Cheng, J | 1 |
| Pang, KS | 1 |
| Adissu, HA | 1 |
| Rauth, AM | 5 |
| Wu, XY | 4 |
| Tanaka, Y | 1 |
| Fukino, S | 1 |
| Oono, T | 1 |
| Kodama, W | 1 |
| Nishimura, K | 2 |
| Hamasaki, N | 1 |
| Marsden, CG | 1 |
| Jensen, RB | 1 |
| Zagelbaum, J | 1 |
| Rothenberg, E | 1 |
| Morrical, SW | 1 |
| Wallace, SS | 1 |
| Sweasy, JB | 1 |
| Sirohi, B | 1 |
| Arnedos, M | 1 |
| Popat, S | 1 |
| Ashley, S | 6 |
| Nerurkar, A | 1 |
| Walsh, G | 5 |
| Johnston, S | 1 |
| Smith, IE | 9 |
| Guo, HY | 1 |
| Cai, Y | 1 |
| Yang, XM | 1 |
| Wang, ZH | 1 |
| Wang, JL | 1 |
| Zhao, XM | 1 |
| Hu, XC | 1 |
| Cowen, RL | 1 |
| Garside, EJ | 1 |
| Fitzpatrick, B | 1 |
| Papadopoulou, MV | 1 |
| Williams, KJ | 2 |
| Paz, MM | 2 |
| Ladwa, S | 1 |
| Champeil, E | 1 |
| Liu, Y | 1 |
| Rockwell, S | 2 |
| Boamah, EK | 1 |
| Bargonetti, J | 1 |
| Callahan, J | 1 |
| Roach, J | 1 |
| Tomasz, M | 2 |
| Reid, LJ | 1 |
| Shakya, R | 1 |
| Modi, AP | 1 |
| Lokshin, M | 1 |
| Cheng, JT | 1 |
| Jasin, M | 1 |
| Baer, R | 1 |
| Ludwig, T | 1 |
| Tanabe, M | 1 |
| Ito, Y | 4 |
| Tokudome, N | 1 |
| Sugihara, T | 1 |
| Miura, H | 1 |
| Takahashi, S | 3 |
| Seto, Y | 1 |
| Iwase, T | 1 |
| Hatake, K | 2 |
| Shuhendler, AJ | 2 |
| Cheung, RY | 2 |
| Manias, J | 1 |
| Connor, A | 1 |
| Santarosa, M | 1 |
| Del Col, L | 1 |
| Tonin, E | 1 |
| Caragnano, A | 1 |
| Viel, A | 1 |
| Maestro, R | 1 |
| Shi, D | 1 |
| Shi, G | 1 |
| Huang, G | 1 |
| Zhang, J | 1 |
| Lartigau, E | 1 |
| Alvarado-Miranda, A | 1 |
| Arrieta, O | 1 |
| Gamboa-Vignolle, C | 1 |
| Saavedra-Perez, D | 1 |
| Morales-Barrera, R | 1 |
| Bargallo-Rocha, E | 1 |
| Zinser-Sierra, J | 1 |
| Perez-Sanchez, V | 1 |
| Ramirez-Ugalde, T | 1 |
| Lara-Medina, F | 1 |
| Naguib, NN | 2 |
| Nour-Eldin, NE | 2 |
| Eichler, K | 2 |
| Zangos, S | 3 |
| Gruber-Rouh, T | 1 |
| Bhatt, L | 1 |
| Fernando, I | 1 |
| Hartmann, J | 1 |
| Getoff, N | 1 |
| Watanabe, K | 1 |
| Otake, T | 1 |
| Yasuda, M | 1 |
| Takenoshita, S | 1 |
| Walker, LC | 1 |
| Thompson, BA | 1 |
| Waddell, N | 1 |
| Grimmond, SM | 1 |
| Spurdle, AB | 1 |
| Hayakawa, T | 1 |
| Zhang, F | 1 |
| Hayakawa, N | 1 |
| Ohtani, Y | 1 |
| Shinmyozu, K | 1 |
| Nakayama, J | 1 |
| Andreassen, PR | 1 |
| Yamada, K | 2 |
| Yakoshi, Y | 1 |
| Yonaiyama, S | 1 |
| Morohashi, S | 1 |
| Morohashi, H | 1 |
| Nishimura, A | 1 |
| Matsuura, O | 1 |
| Fujita, M | 7 |
| Sun, B | 1 |
| Yu, KR | 1 |
| Bhandari, DR | 1 |
| Jung, JW | 1 |
| Kang, SK | 1 |
| Kang, KS | 1 |
| Mitsuhashi, J | 1 |
| Hosoyama, H | 1 |
| Tsukahara, S | 1 |
| Katayama, K | 1 |
| Noguchi, K | 1 |
| Aiba, K | 4 |
| Sugimoto, Y | 1 |
| Gutiérrez-Enríquez, S | 1 |
| Ramón Y Cajal, T | 1 |
| Alonso, C | 1 |
| Corral, A | 1 |
| Carrasco, P | 1 |
| Cornet, M | 1 |
| Sanz, J | 1 |
| Ribas, M | 1 |
| Baiget, M | 1 |
| Diez, O | 1 |
| Kahmann, L | 1 |
| Beyer, U | 1 |
| Mehlhorn, G | 1 |
| Thiel, FC | 1 |
| Strnad, V | 1 |
| Stoiber, N | 1 |
| Hauser, N | 1 |
| Stoiber, B | 1 |
| Hohl, MK | 1 |
| Sohn, C | 2 |
| Eichbaum, MH | 3 |
| Al-Batran, SE | 1 |
| Güntner, M | 1 |
| Pauligk, C | 1 |
| Scholz, M | 1 |
| Chen, R | 1 |
| Beiss, B | 1 |
| Stopatschinskaja, S | 1 |
| Lerbs, W | 1 |
| Harbeck, N | 1 |
| Jäger, E | 1 |
| Aldabbagh, K | 1 |
| Pouderoux, S | 1 |
| Roca, L | 1 |
| Poujol, S | 1 |
| Fabbro, M | 1 |
| Romieu, G | 1 |
| Jacot, W | 1 |
| Wu, S | 1 |
| Lu, X | 1 |
| Zhang, ZL | 1 |
| Lei, P | 1 |
| Hu, P | 1 |
| Wang, M | 1 |
| Huang, B | 1 |
| Xing, W | 1 |
| Jiang, XT | 1 |
| Liu, HJ | 1 |
| Zhu, ZG | 1 |
| Li, WH | 1 |
| Zhu, HF | 1 |
| Fu, N | 1 |
| Shen, GX | 1 |
| Mack, MG | 1 |
| Abskharon, JE | 1 |
| Jost, A | 1 |
| Lillehaug, JR | 3 |
| Vrdoljak, E | 1 |
| Boban, M | 1 |
| Omrcen, T | 1 |
| Hrepic, D | 1 |
| Fridl-Vidas, V | 1 |
| Boskovic, L | 1 |
| Bougen, NM | 1 |
| Yang, T | 1 |
| Chen, H | 1 |
| Lobie, PE | 1 |
| Perry, JK | 1 |
| Liu, XJ | 1 |
| Tkocz, D | 1 |
| Crawford, NT | 1 |
| Buckley, NE | 1 |
| Berry, FB | 1 |
| Kennedy, RD | 1 |
| Gorski, JJ | 1 |
| Harkin, DP | 1 |
| Mullan, PB | 1 |
| Anker, G | 3 |
| Miletic, H | 1 |
| Biswas, K | 1 |
| Das, R | 1 |
| Eggington, JM | 1 |
| Qiao, H | 1 |
| North, SL | 1 |
| Stauffer, S | 1 |
| Burkett, SS | 1 |
| Martin, BK | 1 |
| Southon, E | 1 |
| Sizemore, SC | 1 |
| Pruss, D | 1 |
| Bowles, KR | 1 |
| Roa, BB | 1 |
| Hunter, N | 1 |
| Tessarollo, L | 1 |
| Wenstrup, RJ | 1 |
| Byrd, RA | 1 |
| Sharan, SK | 1 |
| Prasad, P | 1 |
| Shuhendler, A | 1 |
| Schippert, C | 1 |
| Warm, M | 1 |
| Blohmer, JU | 1 |
| du Bois, A | 1 |
| Lück, HJ | 1 |
| Hanson, RN | 1 |
| Hua, E | 1 |
| Labaree, D | 1 |
| Hochberg, RB | 1 |
| Proffitt, K | 1 |
| Essigmann, JM | 1 |
| Croy, RG | 1 |
| Huun, J | 1 |
| Wark, L | 1 |
| Novak, D | 1 |
| Sabbaghian, N | 1 |
| Amrein, L | 1 |
| Jangamreddy, JR | 1 |
| Cheang, M | 1 |
| Pouchet, C | 1 |
| Aloyz, R | 1 |
| Foulkes, WD | 1 |
| Mai, S | 1 |
| Tischkowitz, M | 1 |
| Franke, K | 1 |
| Kettering, M | 1 |
| Lange, K | 1 |
| Kaiser, WA | 1 |
| Hilger, I | 1 |
| Pirnia, F | 1 |
| Schneider, E | 1 |
| Betticher, DC | 1 |
| Borner, MM | 1 |
| Francini, G | 2 |
| Petrioli, R | 2 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Palom, Y | 1 |
| Suresh Kumar, G | 1 |
| Tang, LQ | 1 |
| Musser, SM | 1 |
| Tanabe, K | 1 |
| Kim, R | 1 |
| Inoue, H | 2 |
| Emi, M | 1 |
| Uchida, Y | 1 |
| Toge, T | 3 |
| Xu, Y | 1 |
| Shapiro, CL | 2 |
| Su, F | 1 |
| Hu, X | 1 |
| Jia, W | 1 |
| Gong, C | 1 |
| Song, E | 1 |
| Hamar, P | 1 |
| FUJIMORI, M | 3 |
| SAKAUCHI, G | 1 |
| IZUO, M | 4 |
| ABE, C | 1 |
| MORITA, S | 1 |
| NASHIMOTO, T | 1 |
| ISHIKAWA, S | 1 |
| SADMITSU, H | 1 |
| KAWAI, T | 2 |
| ISHIBASHI, Y | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| SULLIVAN, RD | 1 |
| ZUREK, WZ | 1 |
| SILVA, AR | 1 |
| SMART, CR | 1 |
| ROCHLIN, DB | 1 |
| Kijima, T | 1 |
| Masuda, H | 2 |
| Suzuki, M | 4 |
| Okada, Y | 1 |
| Yano, M | 1 |
| Hyochi, N | 1 |
| Fujii, Y | 2 |
| Kawakami, S | 1 |
| Hayashi, T | 1 |
| Kobayashi, T | 9 |
| Kihara, K | 1 |
| Børresen-Dale, AL | 4 |
| Johnsen, H | 1 |
| Geisler, J | 1 |
| Brammer, I | 1 |
| Herskind, C | 1 |
| Haase, O | 1 |
| Rodemann, HP | 1 |
| Dikomey, E | 1 |
| Shorrocks, J | 1 |
| Tobi, SE | 1 |
| Latham, H | 1 |
| Peacock, JH | 1 |
| Eeles, R | 1 |
| Eccles, D | 1 |
| McMillan, TJ | 1 |
| Giroux, MF | 1 |
| Baum, RA | 1 |
| Soulen, MC | 1 |
| Van Der Heijden, MS | 1 |
| Brody, JR | 1 |
| Kern, SE | 1 |
| Troester, MA | 1 |
| Hoadley, KA | 1 |
| Sørlie, T | 3 |
| Herbert, BS | 1 |
| Shay, JW | 1 |
| Kaufmann, WK | 1 |
| Perou, CM | 2 |
| Loibl, S | 1 |
| von Minckwitz, G | 2 |
| Schwedler, K | 1 |
| Schmidt, KA | 1 |
| Höper, D | 1 |
| Kaufmann, M | 2 |
| Costa, SD | 1 |
| Keller, AM | 1 |
| Mennel, RG | 1 |
| Georgoulias, VA | 1 |
| Nabholtz, JM | 2 |
| Erazo, A | 1 |
| Lluch, A | 1 |
| Vogel, CL | 1 |
| Henderson, IC | 1 |
| Mellars, L | 1 |
| Alland, L | 1 |
| Tendler, C | 1 |
| Peer, D | 1 |
| Dekel, Y | 1 |
| Melikhov, D | 1 |
| Margalit, R | 1 |
| Ahn, B | 1 |
| Kang, D | 1 |
| Kim, H | 1 |
| Wei, Q | 1 |
| Schneeweiss, A | 2 |
| de Rossi, T | 1 |
| Bastert, G | 1 |
| Urruticoechea, A | 1 |
| Archer, CD | 1 |
| Assersohn, LA | 1 |
| Gregory, RK | 3 |
| Verrill, M | 1 |
| Mendes, R | 1 |
| Johnston, SR | 1 |
| Ying, Y | 1 |
| Marcon, N | 1 |
| Yu Wu, X | 1 |
| Kato, S | 1 |
| Kobayashi, H | 1 |
| Makita, S | 1 |
| Kuwabara, H | 1 |
| Raouf, A | 1 |
| Brown, L | 1 |
| Vrcelj, N | 1 |
| To, K | 1 |
| Kwok, W | 1 |
| Huntsman, D | 1 |
| Eaves, CJ | 1 |
| Collier, AC | 1 |
| Pritsos, KL | 1 |
| Pritsos, CA | 1 |
| Alexopoulos, A | 1 |
| Rigatos, G | 1 |
| Stavrinidis, E | 1 |
| Stavrakakis, J | 1 |
| Scartsilas, C | 1 |
| Papacharalambous, A | 1 |
| Arnold, K | 1 |
| Kim, MK | 1 |
| Frerk, K | 1 |
| Edler, L | 1 |
| Savelyeva, L | 1 |
| Schmezer, P | 1 |
| Wiedemeyer, R | 1 |
| Reidt, W | 1 |
| Wurz, R | 1 |
| Wanieck, K | 1 |
| Chu, HH | 1 |
| Puchta, H | 1 |
| Massacesi, C | 1 |
| La Cesa, A | 1 |
| Marcucci, F | 1 |
| Pilone, A | 1 |
| Rocchi, MB | 1 |
| Zepponi, L | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Burattini, L | 1 |
| Fan, C | 1 |
| Nobel, A | 1 |
| Botstein, D | 1 |
| Ling, MT | 1 |
| Wong, YC | 1 |
| Wang, X | 1 |
| Wakiyama, S | 1 |
| Shirabe, K | 1 |
| Nagaie, T | 1 |
| Mathew, J | 1 |
| Asgeirsson, KS | 1 |
| Agrawal, A | 1 |
| Mukherjee, A | 1 |
| Ellis, IO | 2 |
| Cheung, KL | 2 |
| Chan, SY | 2 |
| Robertson, JF | 2 |
| Gast, AS | 1 |
| Bruckner, T | 1 |
| Lyakhovich, A | 1 |
| Surralles, J | 1 |
| Buijs, M | 1 |
| Kamel, IR | 1 |
| Vossen, JA | 1 |
| Georgiades, CS | 1 |
| Hong, K | 1 |
| Geschwind, JF | 1 |
| Maes, T | 1 |
| Heye, S | 1 |
| Demey, W | 1 |
| Van Oosterom, AT | 2 |
| Paridaens, R | 1 |
| Yamauchi, C | 1 |
| Mitsumori, M | 1 |
| Sai, H | 2 |
| Imagunbai, T | 1 |
| Negoro, Y | 1 |
| Sasaki, Y | 3 |
| Hiraoka, M | 1 |
| Shikama, N | 1 |
| Sasaki, S | 1 |
| Takegawa, H | 1 |
| Inoue, T | 1 |
| Teshima, T | 1 |
| Selby, JB | 1 |
| Bauer, RW | 1 |
| Martinez, VG | 1 |
| Stratford, IJ | 1 |
| Clynes, M | 1 |
| O'Connor, R | 1 |
| Mrozek, E | 1 |
| Kolesar, J | 1 |
| Young, D | 1 |
| Allen, J | 1 |
| Villalona-Calero, M | 1 |
| O'Brien, PJ | 1 |
| Nordgard, SH | 1 |
| Alnaes, GI | 1 |
| Hihn, B | 1 |
| Lingjaerde, OC | 1 |
| Liestøl, K | 1 |
| Tsalenko, A | 1 |
| Kristensen, VN | 1 |
| Perez, DJ | 1 |
| Powles, TJ | 9 |
| Gazet, JC | 4 |
| Ford, HT | 5 |
| Coombes, RC | 4 |
| Itoh, J | 1 |
| Nakagawa, H | 1 |
| Sasaki, H | 1 |
| Takahashi, T | 1 |
| Katoh, T | 1 |
| Komuro, K | 1 |
| Hara, Y | 1 |
| Nagayama, A | 1 |
| Gotoh, M | 2 |
| Hagiwara, H | 1 |
| Nakamura, R | 1 |
| Nagasaki, Y | 1 |
| Kataoka, J | 1 |
| Andoh, H | 1 |
| Nakamura, K | 1 |
| Okuma, K | 1 |
| Ota, K | 1 |
| Friedman, MA | 1 |
| Marcus, FS | 1 |
| Cassidy, MJ | 1 |
| Resser, KJ | 1 |
| Kohler, M | 1 |
| Hendrickson, CG | 1 |
| Reynolds, R | 1 |
| Johnson, D | 1 |
| Kilbridge, T | 1 |
| Yu, K | 1 |
| Cruicitt, M | 1 |
| Jouve, M | 1 |
| Palangie, T | 1 |
| Garcia-Giralt, E | 1 |
| Bretaudeau, B | 1 |
| Magdelenat, H | 1 |
| Asselain, B | 1 |
| Pouillart, P | 1 |
| Yap, HY | 1 |
| Valdivieso, M | 1 |
| Blumenschein, G | 2 |
| Hortobagyi, G | 1 |
| Bedikian, A | 1 |
| Lopez, M | 1 |
| Papaldo, P | 1 |
| Di Lauro, L | 1 |
| Barduagni, M | 1 |
| Perno, CF | 1 |
| Barduagni, A | 1 |
| Tashiro, T | 2 |
| Fujimoto, S | 1 |
| Inaba, M | 4 |
| Takatsuka, Y | 1 |
| Sugitachi, A | 1 |
| Tsuchiyama, M | 1 |
| Kitatani, T | 1 |
| Sakamoto, I | 1 |
| Kawahara, T | 1 |
| Nomura, Y | 12 |
| Kanda, K | 1 |
| Tashiro, H | 4 |
| Hamada, Y | 2 |
| Saeki, K | 1 |
| Takahashi, M | 2 |
| Yoshida, K | 2 |
| Ikeuchi, H | 1 |
| Kano, K | 1 |
| Machida, T | 1 |
| Miura, Y | 1 |
| Takeda, T | 2 |
| Yamada, S | 1 |
| Wakui, A | 1 |
| Taguchi, T | 7 |
| Harris, MA | 1 |
| Byrne, PJ | 1 |
| Smith, FP | 1 |
| Ueno, W | 1 |
| Schlesinger, C | 1 |
| Oishi, S | 1 |
| Schein, PS | 1 |
| Stewart, DJ | 2 |
| Maroun, JA | 2 |
| Young, V | 1 |
| Crook, AF | 2 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Bélanger, R | 1 |
| Heringer, R | 2 |
| Garewal, HS | 2 |
| Brooks, RJ | 1 |
| Jones, SE | 1 |
| Miller, TP | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Murphy, J | 1 |
| Tannir, N | 1 |
| Spitzer, G | 1 |
| Dicke, K | 1 |
| Schell, F | 1 |
| DiStefano, A | 1 |
| Amiel, SA | 1 |
| Stewart, JF | 1 |
| Earl, HM | 1 |
| Knight, RK | 2 |
| Rubens, RD | 2 |
| Kubota, T | 7 |
| Kubouchi, K | 3 |
| Koh, J | 4 |
| Asanuma, F | 5 |
| Enomoto, K | 4 |
| Ishibiki, K | 4 |
| Abe, O | 5 |
| Smolianskaia, AZ | 1 |
| Spasibina, TV | 1 |
| Tsuyuki, K | 2 |
| Hanatani, Y | 2 |
| Nakada, M | 1 |
| Yoshimoto, M | 3 |
| Sakamoto, G | 2 |
| Sugano, H | 1 |
| Kasumi, F | 2 |
| Fukami, A | 2 |
| Kuno, K | 1 |
| Ardizzoni, A | 1 |
| Pronzato, P | 2 |
| Conte, PF | 1 |
| Rosso, R | 2 |
| Kurihara, H | 1 |
| Luikart, SD | 1 |
| Witman, GB | 1 |
| Portlock, CS | 1 |
| Meguro, S | 2 |
| Nagata, T | 2 |
| Yokoyama, K | 2 |
| Chinen, T | 2 |
| Yamazaki, H | 5 |
| Kuraishi, Y | 3 |
| Abe, M | 1 |
| Isogai, Y | 2 |
| Ogawa, M | 6 |
| Howell, A | 2 |
| Morrison, JM | 1 |
| Bramwell, VH | 1 |
| Harland, RN | 1 |
| Moneypenny, IJ | 1 |
| Kubo, K | 1 |
| Koyama, H | 6 |
| Sakai, K | 1 |
| Terasawa, T | 4 |
| Tominaga, T | 1 |
| Konits, PH | 1 |
| Aisner, J | 1 |
| van Echo, DA | 1 |
| Lichtenfeld, K | 1 |
| Wiernik, PH | 1 |
| Mattsson, W | 1 |
| von Eyben, F | 1 |
| Hallsten, L | 1 |
| Bjelkengren, G | 1 |
| Hamersma, E | 1 |
| Engelsman, E | 1 |
| Chauvergne, J | 3 |
| Durand, M | 5 |
| Brunet, R | 1 |
| Bui, BN | 1 |
| Hoerni, B | 2 |
| Mauriac, L | 5 |
| Perez Manga, G | 1 |
| Madrigal Alonso, PL | 1 |
| Alburquerque Carbuccia, H | 1 |
| Bayle, F | 1 |
| Vialtel, P | 1 |
| Bastrenta, F | 1 |
| Swiercz, P | 1 |
| Dechelette, E | 1 |
| Pin, I | 1 |
| Carpentier, P | 1 |
| Mousseau, M | 1 |
| Schaerer, R | 1 |
| Couderc, P | 1 |
| Cordonnier, D | 1 |
| Nagashima, K | 1 |
| Sakurai, Y | 2 |
| Yamamoto, M | 2 |
| Takahashi, N | 1 |
| Kunii, Y | 1 |
| Kanno, H | 1 |
| Kikuchi, K | 2 |
| Oster, MW | 1 |
| Park, Y | 1 |
| Chang, YC | 1 |
| Falkson, G | 4 |
| Tormey, DC | 1 |
| Crowley, J | 1 |
| Lorenz, M | 2 |
| Wiesner, J | 1 |
| Staib-Sebler, E | 1 |
| Encke, A | 2 |
| Pacini, P | 3 |
| Tucci, E | 2 |
| Algeri, R | 2 |
| Rinaldini, M | 2 |
| Guarnieri, A | 1 |
| Valzelli, S | 1 |
| Neri, B | 2 |
| Xu, C | 1 |
| Meikrantz, W | 1 |
| Schlegel, R | 1 |
| Sager, R | 1 |
| Takeuchi, T | 2 |
| Harris, AL | 1 |
| Horak, E | 1 |
| Aquino, A | 1 |
| Gonnelli, S | 1 |
| Lewis, WG | 1 |
| Walker, VA | 1 |
| Ali, HH | 1 |
| Sainsbury, JR | 1 |
| Tomita, K | 1 |
| Arai, Y | 5 |
| Inaba, Y | 2 |
| Ohashi, K | 1 |
| Ariyoshi, Y | 2 |
| Yu, RC | 1 |
| Peng, XM | 1 |
| Rao, XQ | 1 |
| Ikeda, T | 5 |
| Asaishi, K | 4 |
| Okazaki, M | 4 |
| Okazaki, A | 4 |
| Toda, K | 4 |
| Masuoka, H | 3 |
| Hirata, K | 1 |
| Narimatsu, E | 2 |
| Philpott, NJ | 1 |
| Bevan, DH | 1 |
| Gordon-Smith, EC | 1 |
| Sone, Y | 1 |
| Kido, C | 4 |
| Abe, R | 3 |
| Tsuchiya, A | 2 |
| Koie, H | 2 |
| Ono, K | 2 |
| Abo, S | 2 |
| Saito, K | 2 |
| Tsukamoto, M | 2 |
| Sato, T | 2 |
| Mori, S | 2 |
| Varhaug, JE | 1 |
| Kolnes, J | 1 |
| Søreide, JA | 1 |
| Agostara, B | 2 |
| Gebbia, V | 2 |
| Testa, A | 1 |
| Cusimano, MP | 1 |
| Gebbia, N | 2 |
| Callari, AM | 1 |
| Perrone, F | 3 |
| De Placido, S | 3 |
| Carlomagno, C | 3 |
| Gravina, A | 1 |
| De Laurentiis, M | 3 |
| Del Mastro, L | 1 |
| Gridelli, C | 2 |
| Pagliarulo, C | 2 |
| Bianco, AR | 3 |
| Rzymowska, J | 1 |
| Dyrda, Z | 1 |
| Nuzzo, F | 1 |
| Ruggiero, A | 1 |
| Yoshida, M | 1 |
| Saji, S | 1 |
| Takagi, H | 1 |
| Takeuchi, S | 1 |
| Tsuda, H | 1 |
| Nimura, Y | 1 |
| Mizumoto, R | 1 |
| Miyazaki, I | 1 |
| Kobayashi, S | 3 |
| Noguchi, M | 1 |
| Hasegawa, S | 1 |
| Suzuki, H | 2 |
| Kojima, Y | 1 |
| Iizuka, I | 1 |
| Tada, K | 1 |
| Montes, A | 1 |
| O'Brien, ME | 3 |
| Ashley, SE | 3 |
| Luckit, J | 1 |
| Treleaven, J | 2 |
| Ishikawa, A | 1 |
| Matsuura, M | 1 |
| Nakajima, N | 2 |
| Ozawa, M | 1 |
| Matsuda, M | 1 |
| Ito, K | 2 |
| Suzuki, K | 1 |
| Toyama, K | 1 |
| Jones, AL | 2 |
| McKinna, JA | 3 |
| Sacks, N | 2 |
| Baum, M | 2 |
| Scheithauer, W | 3 |
| Kornek, G | 2 |
| Haider, K | 2 |
| Kwasny, W | 2 |
| Schenk, T | 1 |
| Pirker, R | 1 |
| Depisch, D | 2 |
| Falkson, CI | 3 |
| Falkson, CB | 2 |
| Falkson, HC | 3 |
| Hortobagyi, GN | 2 |
| Kurihara, T | 1 |
| Higashi, Y | 1 |
| Suemasu, K | 1 |
| Kanoh, T | 1 |
| Tabei, T | 1 |
| Inoue, K | 6 |
| Moskovic, EC | 1 |
| Mansi, JL | 3 |
| King, DM | 1 |
| Murch, CR | 1 |
| Plasswilm, L | 2 |
| Sauer, R | 2 |
| Vinnicombe, SJ | 1 |
| MacVicar, AD | 1 |
| Guy, RL | 1 |
| Sloane, JP | 1 |
| Knee, G | 1 |
| Husband, JE | 1 |
| Griffin, M | 1 |
| Corbishley, C | 1 |
| Makinde, V | 2 |
| Lowndes, S | 2 |
| Quilliam, J | 2 |
| Sutcliffe, R | 2 |
| Baas, P | 1 |
| van Geel, IP | 1 |
| Oppelaar, H | 1 |
| Meyer, M | 1 |
| Beynen, JH | 1 |
| van Zandwijk, N | 1 |
| Stewart, FA | 1 |
| Oka, S | 2 |
| Kitajima, M | 4 |
| Muhonen, T | 1 |
| Jantunen, I | 1 |
| Pertovaara, H | 1 |
| Voutilainen, L | 1 |
| Maiche, A | 1 |
| Blomqvist, C | 1 |
| Pyrhönen, S | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Gobert, C | 2 |
| Bracco, L | 1 |
| Rossi, F | 1 |
| Olivier, M | 1 |
| Tazi, J | 1 |
| Lavelle, F | 1 |
| Larsen, AK | 2 |
| Riou, JF | 1 |
| Morimoto, T | 1 |
| Orita, K | 2 |
| Sugimachi, K | 2 |
| Dohi, K | 2 |
| Monden, Y | 2 |
| Ogawa, N | 1 |
| Seegenschmiedt, MH | 1 |
| Ganssauge, F | 1 |
| Shirouzu, M | 2 |
| Takayama, T | 2 |
| Sekine, I | 1 |
| Fujii, H | 1 |
| Ohtsu, T | 1 |
| Wakita, H | 1 |
| Igarashi, T | 1 |
| Itoh, K | 1 |
| Abe, K | 2 |
| Mark, HF | 1 |
| Naram, R | 1 |
| Santoro, K | 1 |
| Bland, KI | 1 |
| Ashizawa, T | 1 |
| Okamoto, A | 1 |
| Okabe, M | 1 |
| Arai, H | 1 |
| Saito, H | 1 |
| Kasai, M | 2 |
| Gomi, K | 1 |
| Matsumoto, J | 1 |
| Minami, T | 1 |
| Takami, M | 1 |
| Takanishi, K | 1 |
| Matsumine, T | 1 |
| Fernando, IN | 2 |
| Grafton, D | 1 |
| Harmer, CL | 2 |
| MacGrogan, G | 1 |
| Bonichon, F | 2 |
| Trojani, M | 1 |
| de Mascarel, I | 1 |
| Coindre, JM | 1 |
| Kornek, GV | 1 |
| Hejna, M | 2 |
| Raderer, M | 2 |
| Meghdadi, S | 1 |
| Burger, D | 1 |
| Schneeweiss, B | 1 |
| Ota, J | 1 |
| Vorbeck, F | 1 |
| Weinlaender, G | 1 |
| Matsuzaki, SW | 1 |
| Hoshiya, Y | 1 |
| Watanabe, M | 2 |
| Yamada, Y | 2 |
| Koh, JI | 1 |
| Murakami, M | 1 |
| Yoden, E | 1 |
| Kono, K | 1 |
| Okamoto, Y | 1 |
| Maetani, Y | 1 |
| Kobayashi, K | 2 |
| Sasaki, R | 1 |
| Kazawa, N | 1 |
| Sano, A | 1 |
| Kuroda, Y | 1 |
| Oura, S | 1 |
| Sakurai, T | 1 |
| Yoshimura, G | 1 |
| Tamaki, T | 1 |
| Umemura, T | 1 |
| Kokawa, Y | 1 |
| Motomura, K | 1 |
| Noguchi, S | 3 |
| Inaji, H | 2 |
| Miyagawa, T | 1 |
| Toyoda, H | 1 |
| Uesato, K | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Tuğ, T | 1 |
| Karaayvaz, M | 1 |
| Akgül, H | 1 |
| Kusenda, Z | 1 |
| Kerger, J | 1 |
| Awada, A | 1 |
| Geurs, F | 1 |
| Van Vreckem, A | 1 |
| Habboubi, N | 1 |
| Piccart, MJ | 1 |
| Chang, HT | 1 |
| Mok, KT | 1 |
| Tzeng, WS | 1 |
| Ben-Ari, GY | 1 |
| Onogawa, S | 1 |
| Umeda, Y | 1 |
| Kojima, K | 1 |
| Imai, R | 1 |
| Nakagami, K | 1 |
| Tohyama, K | 1 |
| Arai, K | 1 |
| Muro, H | 1 |
| Boccardo, F | 1 |
| Rubagotti, A | 1 |
| Amoroso, D | 1 |
| Perrotta, A | 1 |
| Sismondi, P | 1 |
| Farris, A | 1 |
| Mesiti, M | 1 |
| Gallo, L | 1 |
| Villa, E | 1 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Ebbs, S | 1 |
| McKinna, J | 1 |
| Chang, JC | 1 |
| Takei, H | 1 |
| Iino, Y | 2 |
| Horiguchi, J | 1 |
| Maemura, M | 1 |
| Koibuchi, Y | 1 |
| Nagaoka, H | 1 |
| Yokoe, T | 2 |
| Oyama, T | 1 |
| Morishita, Y | 1 |
| Lale, AM | 1 |
| Jani, PJ | 1 |
| Ellis, PD | 1 |
| Schiebe, ME | 1 |
| Hoffmann, W | 1 |
| Belka, C | 2 |
| Bamberg, M | 1 |
| Kurdistani, SK | 1 |
| Arizti, P | 1 |
| Reimer, CL | 1 |
| Sugrue, MM | 1 |
| Aaronson, SA | 1 |
| Lee, SW | 1 |
| Makris, A | 1 |
| Dowsett, M | 1 |
| Osborne, CK | 1 |
| Trott, PA | 2 |
| Ormerod, MG | 1 |
| Titley, JC | 1 |
| Allred, DC | 1 |
| Geiger, T | 1 |
| Müller, M | 1 |
| Monia, BP | 1 |
| Fabbro, D | 1 |
| Ihnat, MA | 2 |
| Lariviere, JP | 2 |
| Warren, AJ | 3 |
| La Ronde, N | 1 |
| Blaxall, JR | 1 |
| Pierre, KM | 1 |
| Turpie, BW | 1 |
| Hamilton, JW | 3 |
| Schwartz, GK | 1 |
| Farsi, K | 1 |
| Maslak, P | 1 |
| Kelsen, DP | 1 |
| Spriggs, D | 1 |
| Bourgeois, H | 1 |
| Turpin, F | 1 |
| Bouchada, M | 1 |
| Volters, A | 1 |
| Cvitkovic, F | 1 |
| Goupil, A | 1 |
| Janvier, M | 1 |
| Tubiana-Hulin, M | 1 |
| Soulie, P | 1 |
| Berlie, J | 1 |
| Girard, M | 1 |
| Rouëssé, J | 2 |
| Joensuu, H | 1 |
| Holli, K | 1 |
| Heikkinen, M | 1 |
| Suonio, E | 1 |
| Aro, AR | 1 |
| Hietanen, P | 1 |
| Huovinen, R | 1 |
| Crown, J | 2 |
| Tsutsui, S | 2 |
| Murakami, S | 2 |
| Takenaka, Y | 3 |
| Mantovani, F | 1 |
| Banks, L | 1 |
| Hanaoka, K | 1 |
| Tanzawa, F | 1 |
| Tanaka, K | 1 |
| Shibayama, T | 1 |
| Miura, S | 1 |
| Iwabuchi, H | 1 |
| Nakagawa, A | 1 |
| Mitsuhashi, Y | 1 |
| Hisaoka, M | 1 |
| Kaneko, M | 1 |
| Tomida, A | 1 |
| Wataya, Y | 1 |
| Nomura, T | 2 |
| Sasaki, T | 1 |
| Matsuda, A | 1 |
| Tsuruo, T | 1 |
| Kurakata, S | 1 |
| Partridge, SE | 1 |
| Lowdell, CP | 1 |
| Skladanowski, A | 1 |
| Kokufu, I | 1 |
| Taniguchi, H | 1 |
| Kim, YH | 1 |
| Fukuda, K | 2 |
| Yano, T | 1 |
| Kitano, H | 1 |
| Tanner, J | 1 |
| Dunst, J | 1 |
| Moiseenko, VM | 1 |
| Orlova, RV | 1 |
| Giri, AK | 1 |
| Mukhopadhyay, A | 1 |
| Sun, J | 1 |
| Hsie, AW | 1 |
| Ray, S | 1 |
| Cocconi, G | 1 |
| Bisagni, G | 1 |
| Ceci, G | 1 |
| Di Blasio, B | 1 |
| De Lisi, V | 1 |
| Passalacqua, R | 1 |
| Zadro, A | 1 |
| Boni, C | 1 |
| Morandi, P | 1 |
| Savoldi, L | 1 |
| David-Pfeuty, T | 1 |
| Davidson, NG | 1 |
| Davis, AS | 1 |
| Woods, J | 1 |
| Snooks, S | 1 |
| Cheverton, PD | 1 |
| Lauria, R | 1 |
| Vernaglia Lombardi, A | 1 |
| Varriale, E | 1 |
| Costanzo, R | 1 |
| Leo, L | 1 |
| Sugiyama, K | 2 |
| Shimizu, M | 1 |
| Akiyama, T | 1 |
| Tamaoki, T | 1 |
| Yamaguchi, K | 2 |
| Takahashi, R | 1 |
| Eastman, A | 1 |
| Akinaga, S | 1 |
| Nervi, AM | 1 |
| Anthony, SP | 1 |
| Kaltreider, RC | 1 |
| Pesce, CA | 1 |
| Davis, SA | 1 |
| Bini, A | 1 |
| Zompatori, M | 1 |
| Ansaloni, L | 1 |
| Grazia, M | 1 |
| Stella, F | 1 |
| Bazzocchi, R | 1 |
| Saso, R | 1 |
| Kulkarni, S | 1 |
| Mitchell, P | 1 |
| Swansbury, GJ | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Kuan, A | 1 |
| Powles, T | 1 |
| Guarneri, A | 1 |
| Barsanti, G | 1 |
| Bastiani, P | 1 |
| Marzano, S | 1 |
| Fallai, C | 1 |
| Hata, Y | 1 |
| Takahashi, H | 1 |
| Sasaki, F | 1 |
| Ogita, M | 1 |
| Uchino, J | 1 |
| Akasaka, Y | 1 |
| Nakanishi, Y | 1 |
| Sawada, Y | 1 |
| Uchida, N | 1 |
| Tsuzuki, Y | 1 |
| Ando, T | 1 |
| Mochida, Y | 1 |
| Yoshikawa, M | 1 |
| Sekihara, M | 1 |
| Kobayashi, M | 1 |
| Ide, M | 1 |
| Ohno, Y | 1 |
| Kuwano, H | 1 |
| Engels, IH | 1 |
| Stepczynska, A | 1 |
| Stroh, C | 1 |
| Lauber, K | 1 |
| Berg, C | 1 |
| Schwenzer, R | 1 |
| Wajant, H | 1 |
| Jänicke, RU | 1 |
| Porter, AG | 1 |
| Gregor, M | 1 |
| Schulze-Osthoff, K | 1 |
| Wesselborg, S | 1 |
| Raina, V | 1 |
| Sharma, A | 1 |
| Deo, SV | 1 |
| Shukla, NK | 1 |
| Mohanty, BK | 1 |
| Goel, A | 1 |
| Rath, GK | 1 |
| Mustra, DJ | 1 |
| Nishiyama, Y | 1 |
| Komaba, Y | 1 |
| Kitamura, H | 1 |
| Katayama, Y | 1 |
| Fischer, WH | 1 |
| Keiwan, A | 1 |
| Schmitt, E | 1 |
| Stopper, H | 1 |
| Gray, R | 1 |
| McConkey, C | 1 |
| Li, N | 1 |
| van Agthoven, M | 1 |
| Willemse, P | 1 |
| Uyl-de Groot, C | 1 |
| Tokura, H | 2 |
| Masamura, S | 1 |
| Matsui, A | 1 |
| Hojo, T | 1 |
| Kawaguchi, M | 1 |
| Takayama, S | 1 |
| Mitsui, Y | 1 |
| Miyabe, R | 1 |
| Tan, SM | 1 |
| Willsher, PC | 1 |
| Blamey, RW | 2 |
| Su, J | 1 |
| Ciftci, K | 1 |
| Rafii, S | 1 |
| O'Regan, P | 1 |
| Xinarianos, G | 1 |
| Azmy, I | 1 |
| Stephenson, T | 1 |
| Reed, M | 1 |
| Meuth, M | 1 |
| Thacker, J | 1 |
| Cox, A | 1 |
| Kitagawa, K | 1 |
| Yamakado, K | 1 |
| Nakatsuka, A | 1 |
| Tanaka, N | 1 |
| Matsumura, K | 1 |
| Takeda, K | 1 |
| Kawarada, Y | 1 |
| Dixon, AR | 1 |
| Bell, J | 1 |
| Elston, CW | 1 |
| Suzuki, N | 1 |
| Nakazawa, H | 1 |
| Akiyama, H | 1 |
| Murata, M | 1 |
| Takagi, S | 1 |
| Seki, M | 1 |
| Tezuka, T | 1 |
| Shinohara, K | 1 |
| Miura, T | 1 |
| Degardin, M | 1 |
| Hecquet, B | 1 |
| Bonneterre, J | 1 |
| Adenis, A | 1 |
| Pion, JM | 1 |
| Demaille, A | 1 |
| Stein, RC | 1 |
| Bower, M | 1 |
| Law, M | 1 |
| Bliss, JM | 1 |
| Barton, C | 1 |
| Toi, M | 2 |
| Hattori, T | 2 |
| Akagi, M | 1 |
| Inokuchi, K | 1 |
| Astone, A | 1 |
| Cassano, A | 1 |
| Fontana, T | 1 |
| Noviello, MR | 1 |
| Pozzo, C | 1 |
| Barone, C | 1 |
| Dilhuydy, JM | 2 |
| Narasimha, K | 1 |
| Tabuchi, M | 1 |
| Yakushiji, H | 1 |
| Hiroyoshi, M | 1 |
| Matsumoto, S | 1 |
| Fukawa, M | 1 |
| Imaizumi, N | 1 |
| Okushima, K | 1 |
| Kan, N | 1 |
| Kodama, H | 1 |
| Hori, T | 1 |
| Takenaka, A | 1 |
| Yasumura, T | 1 |
| Kato, H | 1 |
| Ogawa, H | 1 |
| Ohsumi, K | 1 |
| Kudo, N | 1 |
| Mukaihara, S | 1 |
| Ghiorghis, A | 1 |
| Talebian, A | 1 |
| Clarke, R | 1 |
| Bilbao, JI | 1 |
| Rebollo, J | 1 |
| Longo, JM | 1 |
| Mansilla, F | 1 |
| Muñoz-Galindo, L | 1 |
| Vieitez, JM | 1 |
| Katano, M | 1 |
| Oogushi, K | 1 |
| Morita, H | 1 |
| Sunaga, T | 1 |
| Matsunaga, H | 1 |
| Yamamoto, H | 2 |
| Hisatsugu, T | 1 |
| Repetto, L | 1 |
| Miglietta, L | 1 |
| Gardin, G | 1 |
| Naso, C | 1 |
| Giudici, S | 1 |
| Merlini, L | 1 |
| Queirolo, P | 1 |
| Campora, E | 1 |
| Pfeiffer, P | 1 |
| Cold, S | 1 |
| Rose, C | 1 |
| Içli, F | 1 |
| Günel, N | 1 |
| Dinçol, D | 1 |
| Karaoğuz, H | 1 |
| Demirkazik, A | 1 |
| Sekiguchi, C | 1 |
| Shimamura, K | 1 |
| Ozawa, I | 1 |
| Inada, T | 1 |
| Hishinuma, S | 1 |
| Shimizu, H | 1 |
| Kotake, K | 1 |
| Ogata, Y | 1 |
| Koyama, Y | 1 |
| Rausa, L | 1 |
| Russo, A | 1 |
| D'Alessandro, N | 1 |
| Palmeri, S | 1 |
| Ngo, EO | 1 |
| Sun, TP | 1 |
| Chang, JY | 1 |
| Wang, CC | 1 |
| Chi, KH | 1 |
| Cheng, AL | 1 |
| Nutter, LM | 1 |
| Sato, H | 3 |
| Ishizuka, K | 1 |
| Hoshi, M | 1 |
| Urushiyama, M | 1 |
| Horikoshi, N | 4 |
| Mukaiyama, T | 4 |
| Mizunuma, N | 1 |
| Itami, S | 1 |
| Hirano, A | 1 |
| Matsuoka, A | 1 |
| Matsumura, T | 1 |
| Werner, A | 1 |
| Mallmann, P | 1 |
| Chronides, A | 1 |
| Diedrich, K | 1 |
| Wagner, U | 1 |
| Krebs, D | 1 |
| Yoshinaka, K | 2 |
| Yagi, M | 1 |
| Ohtagaki, S | 1 |
| Judson, IR | 1 |
| Hardy, JR | 1 |
| Tetsuya, T | 1 |
| Tetsuro, K | 1 |
| Hiroshi, Y | 1 |
| Touru, T | 1 |
| Toshiharu, F | 1 |
| Suguru, K | 1 |
| Susumu, K | 1 |
| Kyuya, I | 1 |
| Osahiko, A | 1 |
| Hirokazu, Y | 1 |
| Watanabe, Y | 2 |
| Mikami, T | 1 |
| Ohba, S | 2 |
| Okazaki, Y | 2 |
| Kanai, T | 1 |
| Monden, M | 1 |
| Sakon, M | 1 |
| Umeshita, K | 1 |
| Ukei, T | 1 |
| Shimano, T | 1 |
| Monden, T | 1 |
| Morimoto, H | 2 |
| Avril, A | 1 |
| Jodrell, DI | 2 |
| Pearson, MC | 1 |
| Sinnett, HD | 2 |
| Yamamoto, T | 1 |
| Josui, K | 1 |
| Fujita, S | 1 |
| Arisawa, Y | 1 |
| Suto, A | 1 |
| Inoue, S | 1 |
| Kuzuoka, M | 1 |
| Kusuyama, T | 3 |
| Okuyama, Y | 1 |
| Shiina, E | 1 |
| Hosoda, Y | 1 |
| Hashimoto, M | 1 |
| Yamamoto, O | 1 |
| Sakai, S | 1 |
| Nio, Y | 1 |
| Imai, S | 1 |
| Shiraishi, T | 1 |
| Tsubono, M | 1 |
| Tseng, CC | 1 |
| Tobe, T | 1 |
| Tsukikawa, S | 2 |
| Oikawa, H | 1 |
| Satoh, T | 1 |
| Morikubo, M | 2 |
| Komoriyama, H | 2 |
| Hagiwara, M | 1 |
| Kanasugi, K | 2 |
| Yamaguchi, S | 2 |
| Akiyoshi, T | 2 |
| Arinaga, S | 2 |
| Nanbara, S | 1 |
| Karimine, N | 1 |
| Takamuku, K | 1 |
| Watanabe, D | 1 |
| Nagamatsu, M | 1 |
| Matsuoka, H | 1 |
| Crivellari, D | 1 |
| Galligioni, E | 1 |
| Frustaci, S | 1 |
| Foladore, S | 1 |
| Lo Re, G | 1 |
| Morassut, S | 1 |
| Monfardini, S | 1 |
| Mori, M | 1 |
| Panasci, L | 1 |
| Shenouda, G | 1 |
| Begin, L | 1 |
| Pollak, M | 1 |
| Reinke, A | 1 |
| Margolese, R | 1 |
| Zaniboni, A | 1 |
| Montini, E | 1 |
| Simoncini, E | 1 |
| Marpicati, P | 1 |
| Arcangeli, G | 1 |
| Meriggi, F | 1 |
| Marini, G | 1 |
| Bayliss, EJ | 1 |
| Stewart, ME | 1 |
| Smyth, JF | 1 |
| Rodger, A | 1 |
| Leonard, RC | 1 |
| Bligh, HF | 1 |
| Bartoszek, A | 1 |
| Robson, CN | 1 |
| Hickson, ID | 1 |
| Kasper, CB | 1 |
| Beggs, JD | 1 |
| Wolf, CR | 1 |
| Imaki, S | 1 |
| Asakura, T | 1 |
| Okamura, R | 1 |
| Fukuda, M | 1 |
| Watanabe, H | 1 |
| Millward, MJ | 1 |
| Hendrick, A | 1 |
| Cantwell, BM | 1 |
| Funahashi, H | 1 |
| Sato, Y | 2 |
| Imai, T | 1 |
| Kato, N | 1 |
| Ando, K | 1 |
| Oike, E | 1 |
| Odaka, K | 1 |
| Ono, M | 1 |
| Narita, T | 1 |
| Kato, M | 1 |
| Nagano, H | 1 |
| Imaoka, S | 1 |
| Masutani, S | 1 |
| Ohashi, I | 1 |
| Ishikawa, O | 1 |
| Oohigashi, H | 1 |
| Yasuda, T | 1 |
| Furukawa, H | 1 |
| Fukuda, I | 1 |
| Friedman, S | 1 |
| Mouriesse, H | 1 |
| Sarrazin, D | 1 |
| Spielmann, M | 1 |
| Fujimoto, K | 1 |
| Oka, T | 1 |
| Morimoto, M | 1 |
| Tada, A | 2 |
| Ueno, K | 2 |
| Nakamura, T | 2 |
| Inagaki, J | 2 |
| Lagler, U | 1 |
| Gattiker, HH | 1 |
| Navarro, M | 1 |
| Bellmunt, J | 1 |
| Balañá, C | 1 |
| Colomer, R | 1 |
| Jolis, L | 1 |
| del Campo, JM | 1 |
| Brambilla, C | 1 |
| Zambetti, M | 1 |
| Ferrari, L | 1 |
| Bonadonna, G | 1 |
| Hisamatsu, K | 2 |
| Yasutake, K | 1 |
| Imamura, Y | 1 |
| Yoshimura, Y | 1 |
| Oya, M | 1 |
| Matsushita, K | 1 |
| Hozumi, T | 1 |
| Katou, J | 1 |
| Okutani, T | 1 |
| Irie, K | 1 |
| Iwanaga, T | 2 |
| Wada, A | 2 |
| Maruo, K | 1 |
| Ohnishi, Y | 1 |
| Ueyama, Y | 1 |
| Umemoto, S | 1 |
| Lyss, AP | 1 |
| Luedke, SL | 1 |
| Einhorn, L | 1 |
| Luedke, DW | 1 |
| Raney, M | 1 |
| A'Hern, RP | 1 |
| Fisher, C | 1 |
| Menichetti, ET | 1 |
| Silva, RR | 1 |
| Tummarello, D | 1 |
| Miseria, S | 1 |
| Torresi, U | 1 |
| Cellerino, R | 1 |
| Kitsukawa, K | 1 |
| Shimizu, T | 1 |
| Komatsu, M | 1 |
| Sugenoya, A | 1 |
| Senga, O | 3 |
| Iida, F | 3 |
| Ingle, JN | 1 |
| Mailliard, JA | 1 |
| Schaid, DJ | 1 |
| Krook, JE | 1 |
| Gerstner, JB | 1 |
| Pfeifle, DM | 1 |
| Marschke, RF | 1 |
| Long, HJ | 1 |
| McCormack, GW | 1 |
| Foley, JF | 1 |
| Zhou, JC | 1 |
| Feng, FY | 1 |
| Sun, Y | 1 |
| Wang, QL | 1 |
| Zeng, WY | 1 |
| Liu, YY | 1 |
| Craft, PS | 1 |
| Pembrey, RG | 1 |
| Marks, A | 1 |
| Goodman, A | 1 |
| Dougherty, S | 1 |
| Ashford, R | 1 |
| Iveson, TJ | 1 |
| Morton, AR | 1 |
| Anderson, H | 1 |
| Ebata, T | 1 |
| Totsuka, M | 1 |
| Hayasaka, H | 1 |
| Sato, N | 1 |
| Hirai, T | 1 |
| Ogawa, T | 1 |
| Ishida, T | 1 |
| Fujita, F | 4 |
| Shimozuma, K | 4 |
| Belpomme, D | 1 |
| Cour, V | 1 |
| Gisselbrecht, C | 1 |
| Le Rol, A | 1 |
| Mignot, L | 1 |
| Marty, M | 1 |
| Godeffroy, W | 1 |
| Maral, J | 1 |
| Sakamoto, Y | 2 |
| Inaba, H | 2 |
| Yamauchi, T | 1 |
| Adachi, I | 1 |
| Tsuchihashi, T | 1 |
| Di Costanzo, F | 1 |
| Gori, S | 1 |
| Tonato, M | 1 |
| Buzzi, F | 1 |
| Crino, L | 1 |
| Grignani, F | 1 |
| Davis, S | 1 |
| Kasuga, Y | 2 |
| Hanamura, N | 2 |
| Oota, H | 1 |
| Katsuyama, T | 1 |
| Tsuchiya, S | 1 |
| David, M | 1 |
| Chow, S | 1 |
| Roscoe, J | 1 |
| Cattran, DC | 1 |
| Aspegren, K | 1 |
| Landberg, T | 1 |
| Akimoto, M | 1 |
| Kimura, M | 1 |
| Sawano, A | 1 |
| Iwasaki, H | 1 |
| Nakajima, Y | 1 |
| Matano, S | 1 |
| Yokozawa, T | 1 |
| Terai, N | 1 |
| Kaneko, G | 1 |
| Ueda, H | 1 |
| Yano, K | 1 |
| Kakuta, T | 1 |
| Endo, T | 3 |
| Aoki, T | 2 |
| Wada, T | 2 |
| Koba, F | 1 |
| Tsuji, H | 1 |
| Ahmann, FR | 1 |
| Pugh, R | 1 |
| Chen, JT | 1 |
| Fujimoto, I | 1 |
| Yamauchi, K | 1 |
| Hasumi, K | 1 |
| Masubuchi, K | 1 |
| Sakamoto, A | 1 |
| Cruciani, G | 1 |
| Tienghi, A | 1 |
| Molinari, AL | 1 |
| Rosti, G | 1 |
| Turci, D | 1 |
| Marangolo, M | 1 |
| Origasa, H | 1 |
| Ogasahara, K | 1 |
| Takeda, R | 1 |
| Nishizawa, F | 1 |
| Yoshimura, T | 1 |
| Denno, R | 1 |
| Adachi, Y | 1 |
| Takahashi, J | 1 |
| Kohno, Y | 1 |
| Bada, K | 1 |
| Ohbayashi, M | 1 |
| Dees, A | 1 |
| Verweij, J | 1 |
| van Putten, WL | 1 |
| Stoter, G | 1 |
| D'Elia, JA | 1 |
| Aslani, M | 1 |
| Schermer, S | 1 |
| Cloud, L | 1 |
| Bothe, A | 1 |
| Dzik, W | 1 |
| Sakata, A | 1 |
| Adhvaryu, SG | 1 |
| Rawal, UM | 1 |
| Patel, JV | 1 |
| Patel, DD | 1 |
| Balar, DB | 1 |
| Miyauchi, K | 1 |
| Nishizawa, Y | 3 |
| Shinozuka, K | 1 |
| Miyake, Y | 1 |
| Ozawa, H | 1 |
| Ballen, KK | 1 |
| Weiss, ST | 1 |
| Godfrey, TE | 1 |
| Budd, GT | 1 |
| Garcia, R | 1 |
| Medendorp, S | 1 |
| Shepard, K | 1 |
| Purvis, J | 1 |
| Bukowski, R | 1 |
| Motoki, R | 1 |
| Hottenrott, C | 1 |
| Reimann-Kirkowa, M | 1 |
| Ishikawa, H | 1 |
| Murayama, N | 1 |
| Kasahara, M | 1 |
| Ikoma, M | 1 |
| Yoshida, H | 1 |
| Shimada, A | 1 |
| Hayano, K | 1 |
| Fukui, H | 1 |
| Otsuka, Y | 1 |
| Hattori, S | 1 |
| Wells, JJ | 1 |
| Nostrant, TT | 1 |
| Wilson, JA | 1 |
| Gyves, JW | 1 |
| Rosner, D | 1 |
| Nemoto, T | 1 |
| Lane, WW | 1 |
| Sulkes, A | 1 |
| Gez, E | 1 |
| Pfeffer, MR | 1 |
| Catane, R | 1 |
| Isacson, R | 1 |
| Biran, S | 1 |
| Shiba, E | 2 |
| Nishi, M | 1 |
| Kajitani, T | 1 |
| Lefebvre, B | 1 |
| Kabuto, T | 1 |
| Perren, TJ | 1 |
| Blackledge, G | 1 |
| Mould, JJ | 1 |
| Chetiyawardana, AD | 1 |
| Morrison, M | 1 |
| Hancock, A | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Nishiyama, M | 1 |
| Yamaguchi, M | 1 |
| Niimoto, M | 1 |
| Villani, F | 1 |
| Comazzi, R | 1 |
| Lacaita, G | 1 |
| Guindani, A | 1 |
| Genitoni, V | 1 |
| Volonterio, A | 1 |
| Brambilla, MC | 1 |
| Kvalheim, G | 1 |
| Gundersen, S | 1 |
| Hager, B | 1 |
| Fodstad, O | 1 |
| Radford, JA | 1 |
| Lenaz, L | 1 |
| Eckhardt, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063] | Phase 2 | 9 participants (Actual) | Interventional | 2013-04-25 | Completed | ||
| Pilot Study: Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging[NCT02798484] | 61 participants (Actual) | Interventional | 2016-06-21 | Completed | |||
| A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression[NCT00005908] | Phase 2 | 30 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (Paclitaxel, Carboplatin) | 3 |
| Arm 2 (Veliparib, Paclitaxel, Carboplatin) | 3 |
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) |
|---|---|
| Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 9 |
| Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 20 |
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 8 | 2 |
| Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 7 | 13 |
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Dose A & B-Cohort 1 & 2-Arm 1 & 2-Docetaxel & Capecitabine | 8 | 13 |
Overall response rate is defined as the percentage of participants with a CR (complete disappearance of all target lesions), PR (a 30% decrease in the sum of the longest diameter of target lesions) determined by clinical measurements per the Response Evaluation Criteria in Solid Tumors (RECIST) and/or a complete pathologic response (disappearance of all invasive tumor pathologically or presence of ductal carcinoma in situ) per the Chevallier criteria. For details about the RECIST or Chevallier criteria see the protocol link module. (NCT00005908)
Timeframe: 6 years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Complete pathologic response | |
| Dose A & B-Cohort 1 & 2-Arm 1& 2-Docetaxel & Capecitabine | 31 | 59 | 10 |
25 reviews available for mitomycin and Breast Cancer
| Article | Year |
|---|---|
A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Humans; Mitochondria; Mitomycin; Neoplasm Recurrence, | 2018 |
Gene therapy approaches to enhance bioreductive drug treatment.
Topics: Alkylating Agents; Animals; Anthraquinones; Breast Neoplasms; Cytochrome P-450 Enzyme System; Cytoch | 2008 |
Mitomycin C in patients with gynecological malignancies.
Topics: Breast Neoplasms; Cytostatic Agents; Female; Genital Neoplasms, Female; Humans; Mitomycin; Salvage T | 2010 |
Rationale for mitomycin and irinotecan use in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2003 |
[Cyclophosphamide-induced bladder cancer: three case reports].
Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; | 2003 |
Growth factors and angiogenesis in breast cancer.
Topics: Antigens, Differentiation, Myelomonocytic; Breast Neoplasms; Drug Resistance; ErbB Receptors; Female | 1993 |
["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical T | 1994 |
Mitomycin: its evolving role in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Melphalan; Methotr | 1993 |
[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1996 |
[CMF or CAF combination chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1996 |
[Benefits of adjuvant chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 1997 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
[Intra-arterial infusion chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Admin | 2002 |
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1992 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1992 |
Breast cancer developing after chemotherapy for osteosarcoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Non | 1991 |
Mitomycin-C and vinblastine in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
Hemolytic-uremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1987 |
Fatal acute respiratory failure following vinblastine and mitomycin administration for breast cancer.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Hypersen | 1988 |
Mitomycin C in advanced breast cancer: an update.
Topics: Breast Neoplasms; Female; Humans; Mitomycin; Mitomycins | 1988 |
Mitomycin C in the chemotherapy of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mitomycin; Mitomyc | 1988 |
Mitomycin-C in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mitomycin; Mitomyc | 1985 |
Mitomycin C in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Mitom | 1985 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
86 trials available for mitomycin and Breast Cancer
| Article | Year |
|---|---|
Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Chemoembolization, Therapeutic; Colorect | 2013 |
Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 2008 |
Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2011 |
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia | 2012 |
Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2004 |
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2004 |
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Sur | 2005 |
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2006 |
Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Me | 2007 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Top | 2008 |
5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): an effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1983 |
[Metastatic breast cancer: controlled trial of chemotherapy with and without hormones].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1984 |
Treatment of advanced breast cancer with two doxorubicin-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1984 |
[Present status of endocrine therapy of breast cancer: a surgeon's view].
Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Combine | 1984 |
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mitomycin; Mitomycins; N | 1980 |
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Clinical Trials a | 1982 |
A pilot study of mitomycin-C and tamoxifen (MT) versus dibromodulcitol, adriamycin, and tamoxifen (DAT).
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1982 |
Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administ | 1994 |
Intra-arterial chemotherapy in patients with breast cancer: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1995 |
[The value of hepatic arterial infusion chemotherapy for liver metastases--discussion from viewpoints of prevention of hepatic death and QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Fl | 1994 |
[Studies of guben quyu No I combined with chemotherapy in treating cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4-CD8 Ratio; Cyclop | 1994 |
Hepatic arterial infusion chemotherapy for liver metastases from breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluoro | 1994 |
A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1994 |
Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Admin | 1994 |
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1994 |
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1993 |
[A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1993 |
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interact | 1993 |
Primary medical (neo-adjuvant) chemotherapy for operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1993 |
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1993 |
A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Medro | 1993 |
Mitomycin: its evolving role in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Melphalan; Methotr | 1993 |
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 1993 |
[Simultaneous radiochemotherapy in recurrent and metastatic breast neoplasm. Clinical experience].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1995 |
Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Car | 1996 |
Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Filgrastim; G | 1996 |
Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 1996 |
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1996 |
An acute toxicity study on the effects of synchronous chemotherapy and radiotherapy in early stage breast cancer after conservative surgery.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comb | 1996 |
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
Topics: Adult; Aged; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 1996 |
Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1996 |
[Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 1997 |
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1997 |
Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROC
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1997 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1997 |
Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 1998 |
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 1997 |
Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1998 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1998 |
[A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 1999 |
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disea | 1999 |
Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin | 1999 |
FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the 'out-patient' setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Brea | 1999 |
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2000 |
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2000 |
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2001 |
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1992 |
Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1992 |
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chem | 1992 |
Salvage chemotherapy with mitoxantrone and mitomycin with or without methotrexate in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1992 |
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1992 |
Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
[Intrapleural treatment of breast cancer patients with pleural effusions: an analysis of 13 institutes in Kyoto and Shiga Prefectures. Kyoto and Shiga Breast Cancer Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Doxo | 1992 |
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 1992 |
A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dac | 1991 |
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Pro | 1991 |
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1991 |
Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia.
Topics: Alkylating Agents; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diges | 1990 |
Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Indaz | 1990 |
Fixed dose short course mitomycin C with vincristine in advanced pre-treated breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1990 |
[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
Mitomycin-C and vinblastine in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
[Systemic adjuvant therapy in patients with operable breast cancer].
Topics: Androstanols; Breast Neoplasms; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Mit | 1989 |
Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; | 1989 |
Myelosuppression after methotrexate, mitoxantrone, and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clinical Trials as To | 1987 |
High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Medro | 1988 |
[Chemotherapy of breast cancers. Coordinated evolution of therapeutic schemes from 1975 to 1985].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1986 |
Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1987 |
A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; | 1988 |
[Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mitomycin; Mitomyc | 1988 |
291 other studies available for mitomycin and Breast Cancer
| Article | Year |
|---|---|
Structure-activity relationships for mitomycin C and mitomycin A analogues.
Topics: Animals; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Humans; Leukemi | 1991 |
In vitro cytotoxicity of the protoberberine-type alkaloids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Berberine; Berberine Alkaloids; Brain Neoplasms; Breast | 2001 |
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
Topics: Antineoplastic Agents; Benzoxazoles; Biological Products; Breast Neoplasms; Cell Line, Tumor; Cell S | 2008 |
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; | 2009 |
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; | 2010 |
Synthesis and docking studies of novel antitumor benzimidazoles.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, An | 2012 |
Germacrane-Type Sesquiterpenoids with Antiproliferative Activities from Eupatorium chinense.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Ce | 2018 |
Genetic determinants of cellular addiction to DNA polymerase theta.
Topics: Aminoquinolines; Animals; Breast Neoplasms; Cell Line; CRISPR-Cas Systems; DNA Breaks, Double-Strand | 2019 |
Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Body Surface Area; Breast Neoplasms; Combined Modality The | 2020 |
Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 2017 |
Transcatheter Arterial Chemoembolization with Spherical Embolic Agent in Patients with Pulmonary or Mediastinal Metastases from Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemoembolization, Therapeutic; Epirubicin; Fe | 2017 |
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell | 2017 |
Lithium chloride attenuates mitomycin C induced necrotic cell death in MDA-MB-231 breast cancer cells via HMGB1 and Bax signaling.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Scre | 2018 |
Cytotoxicity and apoptosis enhancement in breast and cervical cancer cells upon coadministration of mitomycin C and essential oils in nanoemulsion formulations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cel | 2018 |
Isolated thoracic perfusion in lung metastases from breast cancer: a retrospective observational study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Che | 2019 |
Evaluation of Antitumor Activity and Hepatoprotective Effect of Mitomycin C Solubilized in Chamomile Oil Nanoemulsion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chamomile; Emulsions; Female; Humans; | 2019 |
LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; | 2019 |
Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Resistance, Neop | 2019 |
Riboflavin-targeted polymer conjugates for breast tumor delivery.
Topics: Acrylamides; Antibiotics, Antineoplastic; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Delivery | 2013 |
A very rare side effect of mitomycin-C: psoriasiform drug eruption.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Drug Eruptions; Female; Humans; Middle Aged; Mitomyci | 2013 |
The Fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.
Topics: Alkylating Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fanconi Anemia Complementation Gro | 2014 |
Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Curcumin; Drug Synerg | 2014 |
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cohort Studies; DNA Damage; DNA Mutational Analysis; | 2015 |
Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast N | 2015 |
Fanconi anemia cells with unrepaired DNA damage activate components of the checkpoint recovery process.
Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line; D | 2015 |
Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cape | 2016 |
Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Doxorub | 2016 |
[A Case of Carcinomatous Pericarditis of Breast Cancer Successfully Treated with Intrapericardial Mitomycin C Instillations and Systemic Chemotherapy].
Topics: Aged; Breast Neoplasms; Drainage; Female; Humans; Mitomycin; Pericardial Effusion; Pericarditis; Rec | 2016 |
The Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination Phenotype.
Topics: BRCA2 Protein; Breast Neoplasms; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DN | 2016 |
Platinum-based chemotherapy in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 2008 |
Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cross-Linking Rea | 2008 |
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Topics: Animals; BRCA1 Protein; Breast Neoplasms; Cell Line; Chromosome Aberrations; Cross-Linking Reagents; | 2008 |
Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal | 2009 |
A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Breast Neoplasms; C | 2010 |
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.
Topics: Aging, Premature; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; BRCA1 P | 2009 |
Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2009 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplat | 2009 |
Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modalit | 2009 |
Effect of free radicals on the biological action of genistein in vitro and synergism with mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Combined Modalit | 2009 |
[Therapeutic effects of vinorelbine-based chemotherapy--retrospective study of 65 patients with metastatic or relapsed breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Family; Female; Gene E | 2010 |
MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.
Topics: Breast Neoplasms; Chromatin; Chromosome Breakage; Comet Assay; Cross-Linking Reagents; DNA; DNA Repa | 2010 |
[A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillations of OK-432 and mitomycin C].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Tamponade; Drainage | 2010 |
Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation.
Topics: Adult; Animals; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Division; Extrace | 2010 |
In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Proliferation; Clone | 2010 |
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Female; Genes, BRCA1; Genes, BRCA2; Humans; | 2011 |
Successful remission of extensive liver metastases in a breast cancer patient with acute liver failure using a combined chemotherapy regimen with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Fluorouracil; H | 2010 |
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemot | 2010 |
Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Fre | 2012 |
CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2.
Topics: Animals; Antibiotics, Antineoplastic; Antigen Presentation; Blotting, Western; Breast Neoplasms; Che | 2011 |
Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2011 |
Alterations of the retinoblastoma gene in metastatic breast cancer.
Topics: Adult; Anthracyclines; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulati | 2011 |
Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Damage; Drug Resistance; Endometrial Neoplasm | 2011 |
Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2011 |
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
Topics: Antineoplastic Agents; Base Sequence; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Prolif | 2012 |
Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
Topics: Amino Acid Sequence; Animals; BRCA2 Protein; Breast Neoplasms; Cell Cycle Proteins; Cell Survival; C | 2012 |
Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Doxorub | 2013 |
Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using "click" chemistry.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Click Chemistry | 2012 |
Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Apoptosis; Biopsy; Breast Neoplasms; Cell Line, Tumor; | 2013 |
Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
Topics: Adolescent; Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, In | 2013 |
The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma; Caspase 3; Caspase 7; Caspase 8 | 2002 |
Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C.
Topics: Alkylation; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasm | 2002 |
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Glutathion S transferase pi indicates chemotherapy resistance in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Divis | 2003 |
STUDIES ON REGIONAL PERFUSION AND INTRA-ARTERIAL INFUSION FOR CANCER CHEMOTHERAPY.
Topics: Antineoplastic Agents; Breast Neoplasms; Celiac Artery; Chemotherapy, Cancer, Regional Perfusion; Co | 1964 |
[SUPPLEMENTARY THERAPEUTIC MEASURES TO PREVENT THE RECURRENCE OF BREAST CANCER USED IN ASSOCIATION WITH RADICAL SURGERY].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Humans; Mastectomy; Mechlorethamine; Mito | 1964 |
CANCER CHEMOTHERAPY (MITOMYCIN-C) FOLLOWED BY BONE MARROW TRANSPLANTATION.
Topics: Bone Marrow Transplantation; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Bronchogenic; Choriocarci | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
CHEMOTHERAPY OF BREAST CANCER.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; F | 1965 |
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2003 |
Induction and repair of radiation-induced DNA double-strand breaks in human fibroblasts are not affected by terminal differentiation.
Topics: Apoptosis; Breast Neoplasms; Cell Differentiation; Comet Assay; DNA; DNA Damage; DNA Repair; Female; | 2004 |
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment.
Topics: Alkylating Agents; Breast Neoplasms; Cell Cycle; DNA Damage; Fibroblasts; G1 Phase; Genes, BRCA1; Ge | 2004 |
Chemoembolization of liver metastasis from breast carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcin | 2004 |
Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Fanconi Anemia; Fanconi Anemia Complementation Group D2 | 2004 |
Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cl | 2004 |
Cell-type-specific responses to chemotherapeutics in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Cell Line, Tumor; Doxorubi | 2004 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease P | 2004 |
Repair of mitomycin C cross-linked DNA in mammalian cells measured by a host cell reactivation assay.
Topics: Animals; Breast Neoplasms; Cell Line; Cross-Linking Reagents; DNA Damage; DNA Repair; Fireflies; Gen | 2004 |
Endoscopic stenting of the common bile duct allows successful treatment of a breast cancer patient with excessive liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Common | 2004 |
Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C.
Topics: Absorbable Implants; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell | 2005 |
[What we can learn from a case of medical malpractice].
Topics: Antibiotics, Antineoplastic; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Combined Modality The | 2005 |
Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY.
Topics: Aneuploidy; Antibiotics, Antineoplastic; BRCA2 Protein; Breast; Breast Neoplasms; Cross-Linking Reag | 2005 |
TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death.
Topics: Aerobiosis; Breast Neoplasms; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Enzyme Acti | 2006 |
Second and third line chemotherapy in advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1989 |
Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Topics: Analysis of Variance; Base Sequence; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms, Male; Cell C | 2006 |
A homologue of the breast cancer-associated gene BARD1 is involved in DNA repair in plants.
Topics: Amino Acid Sequence; Arabidopsis; Arabidopsis Proteins; Base Sequence; Breast Neoplasms; DNA Repair; | 2006 |
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2006 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, | 2007 |
[A case of carcinomatous cardiac tamponade due to breast cancer treated with OK-432 and mitomycin C].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2007 |
Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2007 |
FANCD2 depletion sensitizes cancer cells repopulation ability in vitro.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; Dos | 2007 |
Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Baltimore; Breast Ne | 2007 |
Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Breast Neoplasms; Female; Humans; | 2008 |
Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process between 1995 1997 and 1999 2001 surveys.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2008 |
Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: possible mechanisms involved.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blo | 2008 |
On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.
Topics: Analysis of Variance; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2007 |
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibiotics, Antineoplastic; Antimetabolites, | 2008 |
Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1984 |
[Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Capsules; Carcinoma, Hepatocellular; Hepatic Artery; | 1983 |
[Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 1983 |
[Adriamycin, cardiotoxicity--a case report].
Topics: Breast Neoplasms; Doxorubicin; Electrocardiography; Female; Fluorouracil; Heart; Humans; Middle Aged | 1982 |
A phase I-II study of continuous 5-day infusion mitomycin-C.
Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Evaluation; Female; Gastrointestinal Neopl | 1983 |
Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combinat | 1983 |
[Experimental study on the evaluation of antineoplastic effects in the human cancer/nude mouse system].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cyclo | 1983 |
[Pre-operative transcatheter arterial embolization for the patients with locally advanced breast cancers--a newly deviced thrombotic material].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Embolization, Therapeutic; Factor XIII; | 1983 |
[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Thera | 1983 |
[Effect of intracavitary administration of an anticancer agent with glucocorticoid on cancer patients complicated with malignant effusion].
Topics: Antineoplastic Agents; Breast Neoplasms; Dexamethasone; Female; Humans; Male; Mitomycin; Mitomycins; | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Fema | 1983 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer.
Topics: Adult; Aged; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Drug Evaluati | 1984 |
Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1984 |
Combined cytotoxic and endocrine therapy for human breast carcinoma (Br-10) serially transplanted into nude mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mi | 1984 |
[Pharmacokinetics of mitomycin C in cancer patients during prolonged administration of the preparation].
Topics: Breast Neoplasms; Female; Humans; Infusions, Parenteral; Kinetics; Mitomycin; Mitomycins; Neoplasms; | 1984 |
[Experimental combination chemo-radiotherapy on human breast carcinoma (MX-1) transplanted into nude mice].
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Combined Modality Therapy; Human | 1984 |
[Experimental combination chemotherapy against a human breast carcinoma (MX-1) transplanted into nude mice with special reference to the cell kinetics].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Female; Human | 1984 |
[Influence of family history, irradiation and anti-cancer drug (mitomycin C) on the occurrence of multiple primary neoplasms in breast carcinoma patients].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cobalt; Female; Humans; Japan; Middle Ag | 1984 |
Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1984 |
[Experimental chemo- and endocrine-therapy of a human breast carcinoma cell line (MCF-7) in vitro and in vivo].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Line; | 1984 |
Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Res | 1984 |
[Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Hum | 1984 |
Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Humans; L | 1984 |
Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1984 |
[Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1983 |
Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Middle Aged; Mitomycin; Mi | 1981 |
A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1982 |
[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Dru | 1981 |
Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.
Topics: Adult; Breast Neoplasms; Drug Therapy, Combination; Etoposide; Female; Humans; Middle Aged; Mitomyci | 1982 |
[Thrombotic microangiopathy and chronic renal failure caused by mitomycin C in 4 women treated for breast cancer].
Topics: Adult; Breast Neoplasms; Female; Humans; Kidney; Kidney Failure, Chronic; Middle Aged; Mitomycin; Mi | 1982 |
Occurrence of drug resistance in human tumor implanted in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Resistance; Humans; Mice; Mice, Nude; M | 1982 |
[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Topics: Adult; Aged; Angiotensin II; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Pressure; Bre | 1982 |
Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1983 |
[Regional therapy breast cancer liver metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1995 |
The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage.
Topics: Alkaloids; Apoptosis; Breast; Breast Neoplasms; Cell Line, Transformed; DNA Damage; Epithelial Cells | 1995 |
[Chemo- and endocrino-therapy of breast carcinoma xenografts in the dormant or exponential growth phase].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Drug Screenin | 1995 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
[The significance of intra-arterial infusion therapy for neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubici | 1994 |
Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; F | 1993 |
[Primary treatment of locally advanced breast cancer with neoadjuvant chemotherapy].
Topics: Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Fluorouracil; Humans; Middle Ag | 1994 |
Enzyme activities and level of SH groups in breast carcinomas.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; DNA, Neoplasm; Epirubi | 1993 |
[A new approach to intra-arterial infusion chemotherapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; H | 1993 |
[Advanced breast cancer with onset of multi-organ metastases successfully treated with combined loco-regional therapies: a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Ch | 1993 |
[Usefulness of contact thermography for the evaluation of chemotherapeutic effectiveness in breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1993 |
Mammography in the assessment of response to medical treatment of large primary breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neopl | 1993 |
Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 1996 |
Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study.
Topics: Aged; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Dermatitis, Phototoxic; Female; Humans | 1996 |
Potentiation of antitumor activity of mitomycin C by estradiol: studies of human breast carcinoma xenografts serially transplanted into nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Flow C | 1996 |
Modulation of DNA topoisomerase I activity by p53.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cattle; Cell Nucleus; DNA Damage; DNA Topois | 1996 |
Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report.
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Br | 1996 |
A study of induced genotoxicity in MCF-7 cells.
Topics: Adenocarcinoma; Breast Neoplasms; Chromosome Aberrations; DNA Damage; DNA, Neoplasm; Dose-Response R | 1995 |
Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Topics: Animals; Antineoplastic Agents; Biotransformation; Breast Neoplasms; Cell Survival; HeLa Cells; Huma | 1995 |
[A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal | 1996 |
Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relat | 1996 |
Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Coloring Agents; Cyclophosphamide; Dox | 1997 |
[Bone metastases responsive to pamidronate therapy in breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonat | 1997 |
[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1997 |
Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 1997 |
Induction intraarterial chemotherapy for T4 breast cancer through an implantable port-catheter system.
Topics: Adult; Aged; Ambulatory Care; Angiography, Digital Subtraction; Antibiotics, Antineoplastic; Antineo | 1997 |
Treatment of abdominal malignancies using total abdominal stop-flow infusion and hypoxic perfusion.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1997 |
[Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Fadrozole; Femal | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
An unusual complication of chemotherapy: an abscess in the pterygopalatine fossa.
Topics: Abscess; Anti-Bacterial Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Immunos | 1998 |
Mitomycin C-related hemolytic uremic syndrome in cancer patients.
Topics: Adenocarcinoma; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Hemolytic-Uremic Syndr | 1998 |
Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cells, Cultured; Chromoso | 1998 |
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small C | 1997 |
Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, | 1997 |
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; DNA Fra | 1997 |
[Mitomycin-vinorelbine combination as second-line chemotherapy in metastatic cancer of the breast].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1998 |
Prognostic impact of second cancer on the survival of early breast cancer patients.
Topics: Adult; Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1999 |
Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Topics: Acetylcysteine; Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma; C | 1999 |
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformatio | 1999 |
Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1999 |
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.
Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Camptothecin; Catalysis; Cell Line; DNA; DN | 1999 |
[A case of adriamycin and methotrexate-resistant recurrent breast cancer treated with doxifluridine and mitomycin C].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
[Effectiveness of current chemotherapy in metastatic breast cancer resistant to anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1999 |
Antimutagenic effects of centchroman--a contraceptive and a candidate drug for breast cancer in multiple mutational assays.
Topics: Animals; Antimutagenic Agents; Breast Neoplasms; Cells, Cultured; Centchroman; CHO Cells; Contracept | 1999 |
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Lin | 1999 |
UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Cell Survi | 2000 |
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily | 1999 |
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
Malignant proliferating trichilemmal tumor in the skin over the breast: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Squamous | 2000 |
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis.
Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-X Protein; BH | 2000 |
Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1998 |
Detection of mitomycin C-DNA adducts in human breast cancer cells grown in culture, as xenografted tumors in nude mice, and in biopsies of human breast cancer patient tumors as determined by (32)P-postlabeling.
Topics: Aged; Animals; Biopsy; Breast Neoplasms; Clinical Trials as Topic; DNA Adducts; DNA, Neoplasm; Femal | 2001 |
Hemolytic uremic syndrome with intracranial hemorrhage following mitomycin C administration.
Topics: Alkylating Agents; Brain; Breast Neoplasms; Female; Hemolytic-Uremic Syndrome; Humans; Intracranial | 2001 |
Increased formation of micronuclei after hormonal stimulation of cell proliferation in human breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; E | 2001 |
A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2001 |
[Clinical experience of intra-arterial chemotherapy for liver metastases of breast cancer patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Doxo | 2001 |
Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Camptothecin; Cell Cycle; Cel | 2002 |
A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.
Topics: Aged; Amino Acid Substitution; Breast Neoplasms; Cell Survival; DNA Repair; DNA-Binding Proteins; Fe | 2002 |
Preoperative transcatheter arterial infusion chemotherapy for locally advanced breast cancer (stage IIIb) for down-staging and increase of resectability.
Topics: Adult; Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Combined Modality Therapy; Doxorubicin | 2002 |
P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1992 |
[Successfully treated locally advanced breast cancer by intra-arterial infusion chemotherapy: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administr | 1992 |
[A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, I | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
[Intermittent intra-arterial infusion chemotherapy using implantable reservoir for the treatment of hepatic metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 1992 |
In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines.
Topics: Breast Neoplasms; Cell Adhesion; Cell Division; Depression, Chemical; DNA, Neoplasm; Dose-Response R | 1992 |
Neoadjuvant intra-arterial chemotherapy in inflammatory carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
[Strategy for therapy of malignant ascites using MTT assay].
Topics: Antineoplastic Agents; Ascitic Fluid; Breast Neoplasms; Cisplatin; Clinical Protocols; Doxorubicin; | 1992 |
Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1992 |
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Melph | 1991 |
Menadione-induced DNA damage in a human tumor cell line.
Topics: Breast Neoplasms; DNA Damage; DNA Repair; Humans; Mitomycin; Tumor Cells, Cultured; Vitamin K | 1991 |
[Evaluation of induced hypertension chemotherapy (IHC) in ambulatory cancer patients].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Breast | 1991 |
Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1991 |
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].
Topics: Ascites; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon- | 1991 |
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; | 1991 |
[Growth chamber assay, a novel chemosensitivity test which eliminates normal stromal cells].
Topics: Animals; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitum | 1991 |
[Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Screening Assays, | 1991 |
[Effect, recurrence and prognosis of intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--especially, the significance of tumor blood vessels].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluorouracil; | 1991 |
[The efficacy of intra-arterial infusion chemotherapy in patients with metastatic liver tumors].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Catheters, Indwelling; Colonic Neoplasms; Combi | 1991 |
[Enhancement of antitumor activity of mitomycin C against human breast carcinoma xenografts by pretreatment with KM 2210].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Estradiol; | 1990 |
[Experimental studies on subrenal capsule assay using cyclosporin A treated mice--the optimal treatment schedules of CsA and anticancer agents (mitomycin C and 5-fluorouracil)].
Topics: Animals; Body Weight; Breast Neoplasms; Colonic Neoplasms; Cyclosporins; Female; Fluorouracil; Human | 1990 |
Changes in the hormone receptors of human breast carcinoma xenografts in nude mice by treatment with cytotoxic agents.
Topics: Animals; Breast Neoplasms; Carcinoma; Cyclophosphamide; Female; Humans; Mice; Mice, Inbred BALB C; M | 1990 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
[The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer].
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Bone Marrow; Breast | 1990 |
The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer.
Topics: Aged; Breast Neoplasms; Colonic Neoplasms; Combined Modality Therapy; Female; Humans; Immunization, | 1990 |
Cisplatin and mitomycin C in advanced chemotherapy-refractory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Hu | 1990 |
[Intra-arterial infusion chemotherapeutic effect of stage III breast cancer by survival rates].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluorouracil; | 1990 |
[Female with breast cancer, undergoing chemotherapeutic treatment hospitalized because of general deterioration, anemia and renal insufficiency].
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Mit | 1990 |
A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluo | 1990 |
Activation of mitomycin C by NADPH:cytochrome P-450 reductase.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Enzyme Activation; Esche | 1990 |
[UFT-MT therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1990 |
[Clinical efficacy of ifosfamide for liver metastasis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Breast Neoplasms; Doxorubicin; Drug Ad | 1990 |
[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile | 1990 |
Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1990 |
Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line; Cisplatin; DNA; Dose-Response Rel | 1987 |
[Acute dyspnea following intravenous administration of vinblastine/mitomycin C].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dyspnea; Female; H | 1989 |
Mitomycin C and vinblastine in advanced refractory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1989 |
[Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Adm | 1989 |
[Analysis of prognostic factors in patients with locally advanced breast cancer treated with intra-arterial infusion chemotherapy as an induction therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1989 |
Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Fem | 1989 |
[Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice].
Topics: Animals; Biogenic Polyamines; Breast Neoplasms; Colonic Neoplasms; Drug Screening Assays, Antitumor; | 1989 |
Primary medical therapy for operable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1989 |
Etoposide and mitomycin-C in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Etopo | 1989 |
[Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Cytot | 1989 |
[Intra-arterial infusion chemotherapy of locally advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraducta | 1989 |
[Evaluation of combined chemotherapy including high-dose cisplatin in the treatment of malignant tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell L | 1987 |
Veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1987 |
Myelosuppression after methotrexate, mitozantrone, and mitomycin C for treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Female; | 1987 |
Myelotoxicity of methotrexate, mitozantrone, and mitomycin C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Female | 1987 |
[Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin].
Topics: Alopecia; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Female; Human | 1985 |
[An analysis of treatments of recurrent breast cancer in relation to the lesion].
Topics: Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Humans; Lymphatic Metastasis; Medr | 1985 |
[Combination chemotherapy of human gastrointestinal and breast cancer xenografts in nude mice with 5'-deoxy-5-fluorouridine and mitomycin C].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female | 1986 |
[Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1987 |
[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
[Bone metastasis in advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Calcitonin; Cyclop | 1987 |
Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leuko | 1986 |
[A case of bilateral metastatic breast carcinoma from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
[Arterial infusion of combination chemotherapy consisting of adriamycin and mitomycin C for liver metastases of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Adm | 1986 |
[Choice of second-line chemotherapy for advanced breast cancer based on the chemosensitivity assay by in vitro colony assay].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinic Ac | 1986 |
5-Fluorouracil and mitomycin C in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1986 |
[Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Glycyrrhetini | 1986 |
[RI angiography with 99mTc and 201T1-chloride scintigraphy in determining the effectiveness of intra-arterial infusion in chemotherapy of locally advanced and recurrent breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Doxorubicin; Female | 1986 |
[The features of liver metastasis of breast cancer on imaging and its response to arterial infusion chemotherapy].
Topics: Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubi | 1986 |
Enhanced chemosensitivity of cells from malignant effusions under condition of exposure to high temperature.
Topics: Ascitic Fluid; Breast Neoplasms; Cells, Cultured; Colonic Neoplasms; Colony-Forming Units Assay; Dox | 1986 |
[Metastatic brain tumor after chemotherapy of ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Cyclop | 1987 |
Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubici | 1987 |
[Subrenal capsule assay as a chemosensitivity test (III)--Comparison of host reaction, experimental chemotherapy and use of nude mice].
Topics: Animals; Breast Neoplasms; Cell Line; Drug Evaluation, Preclinical; Fluorouracil; Humans; Mice; Mice | 1987 |
[A case of breast cancer with pleural metastasis responding to administration of intrapleural adriamycin and systemic chemotherapy with FEMP].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1987 |
Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe | 1987 |
[Subrenal capsule assay as a chemosensitivity test (V)--Experimental chemotherapy of cyclosporin A-treated mice and nude mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Cy | 1988 |
Increased frequency of sister chromatid exchanges in lymphocytes of breast cancer patients.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Lymphocytes; Middle Aged; Mitomycin; Mitomycins; Post | 1988 |
Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1988 |
[Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cyclophosphamide; Doxorubicin; Female; | 1988 |
[Changes in CT findings in patients with liver metastases of breast cancer during effective intra-arterial infusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Humans; Infusion Pump | 1988 |
Alternating non-cross-resistant chemotherapy for metastatic hormone-independent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1988 |
[Regional therapy of isolated liver metastases from breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling | 1988 |
[Preoperative intra-arterial infusion chemotherapy in locally advanced primary breast cancer-tissue concentrations of 5-fluorouracil and adriamycin, and the histological evaluation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neopl | 1988 |
[Three cases of renal failure associated with microangiopathic hemolytic anemia after mitomycin C therapy].
Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Breast Neoplasms; Female; Fluorouracil; Glomerulonephritis, | 1988 |
Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Female; Floxuridine; Gastroscopy; Humans; Infusions, Intra-Arterial; | 1985 |
[Preliminary results of a phase II study of 5-FU, adriamycin, and mitomycin C (FAM) in combined hepatic infusion in patients with non-resectable metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dr | 1987 |
Chemotherapy induces regression of brain metastases in breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Brain Neoplasms; Breast Neopla | 1986 |
Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Breast Neo | 1986 |
[Preoperative chemotherapy for advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1985 |
The influence of family history of cancer, irradiation and anticancer medication (mitomycin C), on the occurrence of multiple primary neoplasms with breast cancer--statistical analysis by the person-year method.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Japan; Middle Aged; Mitomycin; Mitomycins; Neoplasms, | 1985 |
Mitomycin-C plus metronidazole in advanced carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breas | 1985 |
Intra-arterial infusion chemotherapy as an induction therapy in multidisciplinary treatment for locally advanced breast cancer. A long-term follow-up study.
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1985 |
Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1985 |
[Human tumor clonogenic assay in human breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cells, Cultured; Colony-Forming Units Assay; | 1985 |
[Comparison of human tumor clonogenic and nude mouse-isotope assays in anticancer-agent sensitivity tests].
Topics: Animals; Breast Neoplasms; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Drug Evaluatio | 1985 |
Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1985 |
Intra-arterial infusion of mitomycin C in treatment of breast cancer: occurrence of skin necrosis in irradiated patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Humans; Infusions, Intra-Arteria | 1985 |
Mitomycin C and vinblastine in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1985 |